Adjunctive Therapy With 25-Hydroxyvitamin D and Articles Therefor

ABSTRACT

Methods, compositions, and kits for adjunctive therapy using 25-hydroxyvitamin D are disclosed. The 25-hydroxyvitamin D may be administered with an agent that increases the risk of hypocalcemia, such as cinacalcet or a salt thereof, and/or an anticancer agent. The adjunctive therapy is effective to treat and prevent iatrogenic hypocalcemia and/or secondary hyperparathyroidism, as well as delay cancer progression and the time to a post-treatment skeletal related event.

CROSS-REFERENCE TO RELATED APPLICATIONS

This is a continuation of U.S. patent application Ser. No. 14/866,155,filed Sep. 25, 2015, which is a continuation-in-part of InternationalPatent Application No. PCT/EP2015/068219, filed Aug. 6, 2015, whichclaims the benefit of priority under 35 U.S.C. § 119(e) of U.S.Provisional Patent Application No. 62/034,604 filed Aug. 7, 2014. Thedisclosure of each priority application is hereby incorporated herein byreference.

BACKGROUND

The Vitamin D metabolites known as 25-hydroxyvitamin D₂ and25-hydroxyvitamin D₃ (collectively referred to as “25-hydroxyvitamin D”)are Vitamin D prohormones that contribute to the maintenance of adequatelevels of Vitamin D hormones, calcium and phosphorus in the bloodstream.The prohormone 25-hydroxyvitamin D₂ is produced from Vitamin D₂(ergocalciferol), and 25-hydroxyvitamin D₃ (calcifediol) is producedfrom Vitamin D₃ (cholecalciferol), primarily by one or more enzymeslocated in the liver. The two prohormones also can be produced outsideof the liver from Vitamin D₂ and Vitamin D₃ (collectively referred to as“Vitamin D”) in certain cells, such as enterocytes, which containenzymes identical or similar to those found in the liver.

The Vitamin D prohormones are further metabolized in the kidneys by the1α-hydroxylase enzyme CYP27B1 into potent hormones. The prohormone25-hydroxyvitamin D₂ is metabolized into a hormone known as1α,25-dihydroxyvitamin D₂ (ercalcitriol); likewise, 25-hydroxyvitamin D₃is metabolized into 1α,25-dihydroxyvitamin D₃ (calcitriol). Productionof these hormones from the prohormones also can occur outside of thekidney in cells which contain the required enzyme(s).

The Vitamin D hormones have essential roles in human health which aremediated by intracellular Vitamin D receptors (VDR). The Vitamin Dhormones participate in the regulation of cellular differentiation andgrowth, parathyroid hormone (PTH) secretion by the parathyroid glands,and normal bone formation and metabolism. In particular, the Vitamin Dhormones regulate blood calcium levels by controlling the absorption ofdietary calcium and phosphorus by the small intestine and thereabsorption of calcium by the kidneys. Under normal conditions, actionsof Vitamin D on stimulating intestinal calcium absorption predominate,such that dietary calcium is the main source of serum calcium. Howeverif dietary calcium or vitamin D is insufficient, the parathyroid glandincreases secretion of PTH to enhance calcium mobilization from bone tomaintain serum calcium levels. Excessive hormone levels, whethertransient or prolonged, can lead to abnormally elevated urine calcium(hypercalciuria), blood calcium (hypercalcemia) and blood phosphorus(hyperphosphatemia). Insufficient hormone levels can lead to theopposite syndrome of abnormally low blood calcium levels (hypocalcemia).Vitamin D hormones are also required for the normal functioning of themusculoskeletal, immune and renin-angiotensin systems. Numerous otherroles for Vitamin D hormones are being postulated and elucidated, basedon the documented presence of intracellular VDR in nearly every humantissue.

Left untreated, inadequate Vitamin D supply can cause serious bonedisorders, including rickets and osteomalacia, and may contribute to thedevelopment of many other disorders including osteoporosis,non-traumatic fractures of the spine and hip, obesity, diabetes, muscleweakness, immune deficiencies, hypertension, psoriasis, and variouscancers.

The Institute of Medicine (TOM) of the National Academy of Sciences hasconcluded that an Adequate Intake (AI) of Vitamin D for a healthyindividual ranges from 200 to 600 IU per day, depending on theindividual's age and sex (Standing Committee on the ScientificEvaluation of Dietary Reference Intakes, Dietary reference intakes:calcium, phosphorus, magnesium, vitamin D, and fluoride. Washington,D.C.: National Academy Press (1997), incorporated by reference). The AIfor Vitamin D was defined primarily on the basis of a serum25-hydroxyvitamin D level sufficient to prevent Vitamin D deficiencyrickets or osteomalacia (or greater than or equal to 11 ng/mL). The TOMalso established a Tolerable Upper Intake Level (UL) for Vitamin D of2,000 IU per day, based on evidence that higher doses are associatedwith an increased risk of hypercalciuria, hypercalcemia and relatedsequelae, including cardiac arrhythmias, seizures, and generalizedvascular and other soft-tissue calcification.

Currently available oral Vitamin D supplements are far from ideal forachieving and maintaining optimal blood 25-hydroxyvitamin D levels.These preparations typically contain 400 IU to 5,000 IU of Vitamin D₃ or50,000 IU of Vitamin D₂ and are formulated for quick or immediaterelease in the gastrointestinal tract. When administered at chronicallyhigh doses, as is often required for Vitamin D repletion, these productshave significant, and often severe, limitations.

Abnormalities of Vitamin D signaling and metabolism exist in a widevariety of tumors (Krishnan et al., (2012). Rheum Dis Clin North Am 38,161-178) and are thought to be due to increased expression of CYP24 (Luoet al., (2013) J Steroid Biochem Mol Biol 136, 252-257). Cancer patientsgenerally exhibit vitamin D insufficiency, therefore, calcium resorptionfrom bone calcium stores plays a dominant role in the normalization ofblood calcium levels. Regardless of the cancer type, low serum levels of25-hydroxyvitamin D and decreased VDR activation have been associatedwith increased metastasis. Cancer mortality is usually a consequence ofmetastasis. For certain types of cancer, notably breast and prostate,the bulk of tumor burden at the time of death is in bone. The impact ofmetastasis on bone metabolism and consequent morbidity is considerableand, depending on the origin of the primary tumor, is either osteolytic(e.g., breast, myeloma) or osteoblastic (e.g., prostate) in nature.However, since bone formation and bone resorption are coupled,“osteolytic” and “osteoblastic” categorizations correspond to the netbalance of bone metabolism associated with metastases. A number offactors released from tumors can affect net balance of bone metabolism,including parathyroid hormone related peptide (PTHrP), transforminggrowth factor-β (TGF-β), insulin-like growth factors (IGF), bonemorphogenetic factors (BMP) and platelet-derived growth factors (PDGF).

PTHrP is produced by certain types of cancer cells, such as breast, andcan trigger net bone resorption by stimulating the production of theligand for the receptor activator of NFKB (RANKL) (Rabbani, S. A.(2000). Int J Oncol 16, 197-206.; Soyfoo et al. (2013). Support CareCancer 21, 1415-1419) Like PTH, PTHrP can be regulated by activating theVitamin D signaling pathway (Bhatia et al. (2009). Mol Cancer Ther 8,1787-1798; El Abdaimi et al. (1999). Cancer Res 59, 3325-3328.).Consequently, the use of Vitamin D and related analogs has been proposedto help control excessive hypercalcemia caused by PTHrP overexpressionin breast and prostate cancers (Richard et al. (2005) Crit Rev EukaryotGene Expr 15, 115-132.). The majority of instances of hypercalcemia incancer patients are thought to be related to the production of PTHrP(Motellon et al. (2000) Clin Chim Acta 290, 189-197.). In some cases,hypercalcemia of malignancies has been associated with the use ofVitamin D or calcifediol and is related to elevated PTHrP expression.Like PTH, PTHrP expression can increase expression of CYP27B1, thekidney enzyme responsible for activating calcifediol. Therefore, acancer patient with vitamin D insufficiency and higher than normallevels of PTHrP could potentially express increased levels of unoccupiedCYP27B1; a sudden bolus of calcifediol could cause a surge in1,25-dihydroxyvitamin D and potentially result in hypercalcemic episodes(Motellon et al 2000, supra; Sato et al. (1993). Intern Med 32,886-890.) and further upregulation of CYP24. These hypercalcemicepisodes, in contrast to those caused by PTHrP stimulation of RANKL, aredue to increased rate of intestinal absorption of Ca.

The relationship between the progression of tumor metastases and bonecatabolism is determined to a large extent on the tumor microenvironmentwithin bone. In certain types of cancers, such as prostate cancer, boneformation can be stimulated by TGF-β, IGFs, PDGF and BMPs and thesefactors play an important role in establishing the bonemicroenvironment. These patients can suffer from hypocalcemia, which isthe reduction of serum calcium levels in the blood. Severe hypocalcemiais sometimes referred to as “hungry bone” syndrome. Accordingly, thestate of bone health may be an important determinant of the progressionof the metastatic process, including the tumor cell invasion of bone,the angiogenic response, and tumor cell proliferation, as well asdifferentiation of bone cell precursors into osteoblasts andosteoclasts. There is evidence that vitamin D status may have aninfluence on each of these parameters, suggesting that vitamin Dadequacy may be essential to minimize the progression of bonemetastases. Although numerous clinical studies have attempted to raiseVitamin D levels for the treatment of various cancers, currentlyavailable therapies do not safely raise 25-hydroxyvitamin D levels highenough to establish the impact 25-hydroxyvitamin D has on tumor growthand metastasis or associated morbidities.

Because bone resorption is a common pathophysiology of bone metastasesregardless of primary tumor type, patients are typically treated withbone antiresorptive agents, which inhibit bone resorption by targetingbone osteoclasts to decrease their osteolytic activity. Antiresorptivetherapies, also known as bone-sparing agents, reduce the impact ofcancer-related increases in bone resorption. Antiresorptive agents canprevent or delay skeletal related events (SRE). SRE are defined aspathological fractures, radiation or surgery to bone, and spinal cordcompression, and are used to evaluate the clinical efficacy ofantiresorptive agents because SRE are associated with poor prognosis andquality of life. Because antiresorptive agents can slow bone loss, theyare also prescribed for patients with osteoporosis and other bonedisorders. Examples of antiresorptive agents include bisphosphonatessuch as zoledronic acid, selective estrogen receptor modulators (SERMs),calcitonin, estrogen, and monoclonal antibodies such as denosumab.Treatment with antiresorptive agents also reduces the efficiency ofPTH-stimulated resorption of bone, thus patients must rely on intestinalabsorption of calcium for maintaining serum calcium levels.

One of the most important and immediate side effects of antiresorptiveagents is hypocalcemia. Other therapeutic agents that can increase therisk of hypocalcemia include anticonvulsant agents, corticosteroids,antihypercalcemia agents, antimicrobial agents, and combinationsthereof. Serum calcium is critical for the normal function of nerves andmuscles in the body, and serum calcium levels are tightly regulatedwithin narrow limits in healthy subjects. Hypocalcemia can be asignificant source of morbidity and mortality. Severe hypocalcemia, inwhich serum calcium levels are reduced to below the lower limit ofnormal, can result in life-threatening consequences, including muscletetany and cardiac arrest. Such treatment-induced, also known asiatrogenic, hypocalcemia, can be serious, even fatal, and therefore mustbe controlled.

Following administration of the antiresorptive agent denosumab,hypocalcemia is believed to result directly from the inhibitory effectsof denosumab on the activity and numbers of bone-resorbing osteoclasticbone cells. Clinical studies have suggested reduced levels of calcium inthe blood as soon as one day after initiation of denosumab treatment.Similarly, in a recent study of patients with bone metastases treatedwith the antiresorptive agent zoledronic acid, 39% of the patientsdeveloped hypocalcemia (Zuradelli et al., (2009) Oncologist 14,548-556). Hypocalcemia is one of the most common adverse reactionsresulting in discontinuation of therapy with zoledronic acid ordenosumab.

Another example of a therapeutic agent that can increase the risk ofhypocalcemia is the antihypercalcemia agent cinacalcet (SENSIPAR, AmgenInc., Thousand Oaks, Calif.). Cinacalcet activates calcium-sensingreceptors in the body and lowers serum calcium. See, e.g., U.S. Pat.Nos. 6,001,884 and 6,211,244, incorporated herein by reference.Cinacalcet is currently indicated for treating secondaryhyperparathyroidism in patients having Chronic Kidney Disease (CKD) ondialysis (i.e., CKD Stage 5) and hypercalcemia in patients withparathyroid carcinoma or primary hyperparathyroidism. Cinacalcet maycause significant reductions in serum calcium that can lead tohypocalcemia and/or seizures and is contraindicated for use in patientswho are already hypocalcemic and also is not indicated for use in CKDpatients who are not on dialysis due to the increased risk ofhypocalcemia. It is contemplated that the compositions and methodsherein can be useful in patients having CKD Stage 5, or in anotherembodiment in patients having CKD Stage 4. It is contemplated that thecompositions and methods herein can be useful in patients having CKD andon dialysis, or in another embodiment, patients not on dialysis.

Vitamin D supplementation is therefore recommended for patients onantiresorptive therapy and/or therapy including an agent that increasesthe risk of hypocalcemia such as cinacalcet. The treatment protocols inpublished repeat-dose clinical studies for denosumab have uniformlycalled for denosumab-treated subjects to receive daily supplements ofcalcium (0.5 to 1.0 g or more) and at least 400 to 800 IU vitamin D(cholecalciferol and/or ergocalciferol) in order to preventhypocalcemia. Recommendations for calcium and vitamin D supplementationof denosumab-treated subjects have been included in the FDA-approvedlabeling for denosumab. However, currently available oral vitamin Dsupplements are not optimal for increasing and maintaining serum levelsof either 25-hydroxyvitamin D or 1,25-dihydroxyvitamin D at desirablelevels. The inadequacy of currently available vitamin D supplements atcompletely mitigating hypocalcemia in denosumab-treated subjects ishighlighted by a recent Advisory from Health Canada, which noted thatpostmarketing cases of severe symptomatic hypocalcemia have occurred indenosumab-treated subjects at an estimated rate of 1 to 2%, includingsome cases that were fatal.

Another side effect of antiresorptive agents and other agents thatincrease the risk of hypocalcemia is secondary hyperparathyroidism(SHPT). Decreases in serum calcium can result in increased production ofPTH. Elevated PTH levels are common in patients undergoing treatmentwith antiresorptive agents, indicating an increased vitamin Drequirement. Regulation of blood calcium requires adequate production ofcalcitriol, which stimulates intestinal absorption of dietary calciumand reabsorption of calcium by the kidney. Calcitriol, in concert withelevated PTH, also mobilizes calcium from bone. Adequate calcitriolproduction requires a sufficient supply of the precursor, calcifediol,and the first sign of inadequate calcitriol production is an increase inplasma PTH. PTH stimulates expression of CYP27B1 in the kidney and,thereby, increases conversion of calcifediol to calcitriol. When serumcalcitriol levels are restored to adequate levels, PTH secretiondecreases. If serum calcitriol levels cannot be corrected, as in thecase of a calcifediol supply shortage (i.e., vitamin D insufficiency),plasma PTH remains elevated causing continuous mobilization of calciumfrom bone. A recent study (Berruti et al. (2012) Oncologist 17, 645-652)reported that 82% to 90% of subjects with prostate cancer metastatic tobone and receiving zoledronic acid exhibited elevated PTH, compared to17% of patients receiving placebo. The elevated PTH was negativelyassociated with survival. The prevalence and persistence of SHPT inpatients on antiresorptive therapies even though supplemented withVitamin D and calcium indicates that appropriate supplementationregimens have not yet been clearly defined for this patient population,and the efficacy of antiresorptive agents can be limited by even mildhypocalcemia and/or SHPT.

Clearly, an alternative approach to currently available Vitamin Dsupplementation is needed in patients with cancer and in patientstreated with an agent that increases the risk of hypocalcemia.

SUMMARY

The present disclosure relates to 25-hydroxyvitamin D therapy asadjunctive therapy and/or to treat cancer in a patient.

In one aspect, a method of treating or preventing iatrogenichypocalcemia and/or secondary hyperparathyroidism in a patient treatedwith an agent that increases the risk of hypocalcemia comprisesadministering to the patient an effective amount of 25-hydroxyvitamin D,for example, administering a pharmaceutical formulation comprising (a) a25-hydroxyvitamin D compound and (b) an agent that increases the risk ofhypocalcemia, optionally cinacalcet or a salt thereof, described herein.

In another aspect, a method of increasing bone mineral density in apatient treated with an agent that increases the risk of hypocalcemiacomprises administering to the patient an effective amount of25-hydroxyvitamin D.

In another aspect, a method of decreasing the blood level of a boneresorption marker in a patient treated with an agent that increases therisk of hypocalcemia comprises administering to the patient an effectiveamount of 25-hydroxyvitamin D. In another aspect, a method of treatingbone pain in a patient treated with an agent that increases the risk ofhypocalcemia comprises administering to the patient an effective amountof 25-hydroxyvitamin D.

In another aspect, a method of increasing the time to the firstpost-treatment skeletal-related event in a patient treated with an agentthat increases the risk of hypocalcemia comprises administering to thepatient an effective amount of 25-hydroxyvitamin D. In another aspect, amethod of treating a patient treated with an agent that increases therisk of hypocalcemia comprises administering to the patient an effectiveamount of 25-hydroxyvitamin D to effectively and safely restore blood25-hydroxyvitamin D levels to at least 30 ng/mL and to maintain blood25-hydroxyvitamin D levels at such optimal levels.

In any of the methods disclosed herein, the agent that increases therisk of hypocalcemia is optionally selected from the group consisting ofan antiresorptive agent, an anti-convulsant agent, a corticosteroid, anantihypercalcemia agent, an antimicrobial agent, and combinationsthereof. In one aspect, the agent that increases the risk ofhypocalcemia is an antiresorptive agent, optionally selected from thegroup consisting of bisphosphonates (e.g., zoledronic acid, alendronate,risedronate, ibandronate, etidronate, and pamidronate), selectiveestrogen receptor modulators (e.g., raloxifene), calcitonin, hormones(e.g., estrogen), and monoclonal antibodies (e.g., denosumab). Inanother aspect, the agent that increases the risk of hypocalcemia is anantihypercalcemia agent, for example, cinacalcet.

In one aspect, a method of treating secondary hyperparathyroidism inChronic Kidney Disease in a patient on dialysis comprises administeringto said patient an effective amount of a 25-hydroxyvitamin D compound bymodified release and an effective dose of cinacalcet or a salt thereofin an amount of less than about 360 mg daily, wherein said effectiveamount of cinacalcet or a salt thereof is a reduced dose compared to theeffective dose of cinacalcet or a salt thereof in the absence of said25-hydroxyvitamin D administration.

In another aspect, a method of treating hypercalcemia in a patient withparathyroid carcinoma comprises administering to said patient aneffective amount of a 25-hydroxyvitamin D compound by modified releaseand an effective dose of cinacalcet or a salt thereof in an amount ofless than about 360 mg daily, wherein said effective amount ofcinacalcet or a salt thereof is a reduced dose compared to the effectivedose of cinacalcet or a salt thereof in the absence of said25-hydroxyvitamin D administration.

In still another aspect, a method of treating severe hypercalcemia in apatient with primary hyperparathyroidism who is unable to undergoparathyroidectomy comprises administering to said patient an effectiveamount of a 25-hydroxyvitamin D compound by modified release and aneffective dose of cinacalcet or a salt thereof in an amount of less thanabout 360 mg daily, wherein said effective amount of cinacalcet or asalt thereof is a reduced dose compared to the effective dose ofcinacalcet or a salt thereof in the absence of said 25-hydroxyvitamin Dadministration.

In another aspect, a method of lowering elevated serum parathyroidhormone levels in a patient having a bone metastasis and treated with anantiresorptive agent comprises administering an effective amount of25-hydroxyvitamin D. In another aspect, a method of stabilizing serumcalcium levels in a patient having a bone metastasis and treated with anantiresorptive agent comprises administering an effective amount of25-hydroxyvitamin D. In still another aspect, a method of treatinghungry bone syndrome comprises administering an effective amount of25-hydroxyvitamin D to a patient in need of thereof.

In any of the methods of the present disclosure, the patient optionallyhas osteoporosis and/or cancer. In one aspect, a method of managingiatrogenic hypocalcemia and secondary hyperparathyroidism in a patientwith a bone metastasis treated with an antiresorptive agent comprisesadministering an effective amount of 25-hydroxyvitamin D to prevent orreverse the iatrogenic hypocalcemia and lower the patient's serumparathyroid hormone level. In another aspect, a method of mitigatingcancer progression and/or a skeletal related event in a patient with abone tumor, optionally a bone metastasis from a solid tumor, comprisestreating the patient with (a) an anticancer agent; (b) an antiresorptiveagent; and (c) a 25-hydroxyvitamin D compound, wherein the combinationof (a), (b), and (c) is effective to slow tumor growth and/or metastasisand/or increase the time to the first post-treatment skeletal-relatedevent. In still another aspect, a method of treating a patient havingcancer and a bone metastasis comprises the administration of (a) aprophylactic and continuing course of an effective amount of25-hydroxyvitamin D to stabilize 25-hydroxyvitamin D levels and calciumlevels in the patient without causing or exacerbating hypercalcemia;followed by (b) treatment with an agent known to increase the risk ofiatrogenic hypocalcemia, wherein the treatment in step (a) preventsand/or treats the iatrogenic hypocalcemia in the patient.

In another aspect, a method of mitigating the progression of cancer inthe bone in a patient comprises administering an effective amount of25-hydroxyvitamin D. In another aspect, a method of inhibiting theproliferation and migration of cancer cells comprises administering aneffective amount of 25-hydroxyvitamin D to a patient in need thereof. Inanother aspect, a method of treating cancer in a patient comprisesadministering to the patient an effective amount of a combination of25-hydroxyvitamin D and an anticancer agent. In any of the foregoingmethods, the patient optionally has a cancer selected from the groupconsisting of bone cancer, bladder cancer, breast cancer, colon cancer,endometrial cancer, kidney cancer, leukemia, lung cancer, lymphoma,pancreatic cancer, prostate cancer, skin cancer, thyroid cancer, andmetastatic forms thereof.

The present disclosure also relates to the use of 25-hydroxyvitamin D,optionally in a modified release formulation, as adjunctive therapy totreat hypocalcemia in a patient in need thereof. In one aspect, thedisclosure provides a pharmaceutical composition comprising (a)25-hydroxyvitamin D and (b) an agent that increases the risk ofhypocalcemia and/or an anticancer agent. In one aspect, the disclosureprovides a pharmaceutical formulation for oral administration comprising(a) a 25-hydroxyvitamin D compound and (b) an agent that increases therisk of hypocalcemia, optionally cinacalcet or a salt thereof. Forexample, in one embodiment, the pharmaceutical formulation comprises afirst region comprising a 25-hydroxyvitamin D compound and a secondregion comprising an agent that increases the risk of hypocalcemia,optionally cinacalcet or a salt thereof.

In another aspect, the disclosure provides a kit comprising (a)25-hydroxyvitamin D; (b) an agent that increases the risk ofhypocalcemia and/or an anticancer agent; and (c) instructions forco-administering effective amounts of (a) and (b) to a patient in needthereof.

In another aspect, a method or pharmaceutical formulation according tothe present disclosure comprises 25-hydroxyvitamin D in a modifiedrelease formulation, optionally an oral modified release formulation. Inanother aspect, the 25-hydroxyvitamin D is administered in a sterileintravenous formulation. In various aspects, the 25-hydroxyvitamin D canbe selected from the group consisting of 25-hydroxyvitamin D₂,25-hydroxyvitamin D₃, 25-hydroxyvitamin D₄, 25-hydroxyvitamin D₅,25-hydroxyvitamin D₇ and combinations thereof. In another aspect, amethod or pharmaceutical formulation according to the present disclosurecomprises cinacalcet or a salt thereof in an immediate releaseformulation, optionally an oral rapidly dissolving formulation.

For the compositions and methods described herein, optional features,including but not limited to components, compositional ranges thereof,substituents, conditions, and steps, are contemplated to be selectedfrom the various aspects, embodiments, and examples provided herein.

Further aspects and advantages will be apparent to those of ordinaryskill in the art from a review of the following detailed description,taken in conjunction with the drawings. While the compositions andmethods are susceptible of embodiments in various forms, the descriptionhereafter includes specific embodiments with the understanding that thedisclosure is illustrative and is not intended to limit the invention tothe specific embodiments described herein.

DETAILED DESCRIPTION

The present disclosure relates to 25-hydroxyvitamin D therapy asadjunctive therapy and in the treatment of cancer. In variousembodiments, the disclosure provides methods for dosing a subjectreceiving treatment with an agent that increases the risk ofhypocalcemia and/or an anticancer agent with an effective amount of25-hydroxyvitamin D, optionally as a modified release oral formulationor administered in intravenous form. The administration of25-hydroxyvitamin D to a patient, for example, in a pharmaceuticalformulation comprising 25-hydroxyvitamin D and an agent that increasesthe risk of hypocalcemia, such as cinacalcet or a salt thereof,according to the present disclosure effectively achieves one or more ofthe following: (a) treats or prevents hypocalcemia, e.g., iatrogenichypocalcemia; (2) treats or prevents secondary hyperparathyroidism,e.g., in a patient having Chronic Kidney Disease; (3) increases bonemineral density; (4) decreases the blood level of a bone resorptionmarker; (5) decreases bone pain; (6) increases the time to the firstpost-treatment skeletal related event; (6) safely restores blood25-hydroxyvitamin D levels to optimal levels (defined for human subjectsas greater than 30 ng/mL) and maintains blood 25-hydroxyvitamin D levelsat such optimal levels without causing hypocalcemia or hypercalcemia;(7) lowers elevated serum parathyroid hormone levels; (8) stabilizesserum calcium levels; (9) treats hungry bone syndrome; (10) managesiatrogenic hypocalcemia and secondary hyperparathyroidism in a patientwith a bone tumor; (11) mitigates cancer progression, i.e., byinhibiting the proliferation and/or migration of cancer cells; (12)restores or maintains serum calcium levels to at least 8.0 mg/dL,optionally at least 8.3 mg/dL or 8.5 mg/dL, further optionally up to11.6 mg/dL, e.g. in a range of 8.3 mg/dL and 11.6 mg/dL, corrected forserum albumin; (13) safely increases serum levels of1,25-dihydroxyvitamin D, optionally to at least 50 pg/mL; (14) achievesor maintains safe serum phosphorus levels and prevents or treatshypophosphatemia; (15) has a positive effect on the serum level of amarker of bone formation; (16) maintains or decreases tumor burden;and/or (17) treats hypercalcemia, e.g., in a patient with parathyroidcarcinoma or primary hyperparathyroidism, optionally a patient who isunable to undergo parathyroidectomy.

The present disclosure also relates to the use of 25-hydroxyvitamin D asadjunctive therapy to treat hypocalcemia, and compositions and kitscomprising (a) 25-hydroxyvitamin D and (b) an agent that causeshypocalcemia, such as cinacalcet, and/or an anticancer agent.

The methods, compositions, and kits of the present disclosure arecontemplated to include embodiments including any combination of one ormore of the additional optional elements, features, and steps furtherdescribed below, unless stated otherwise.

In jurisdictions that forbid the patenting of methods that are practicedon the human body, the meaning of “administering” a composition to ahuman subject shall be restricted to prescribing a controlled substancethat a human subject will self-administer by any technique (e.g.,orally, inhalation, topical application, injection, insertion, etc.).The broadest reasonable interpretation that is consistent with laws orregulations defining patentable subject matter is intended. Injurisdictions that do not forbid the patenting of methods that arepracticed on the human body, “administering” compositions includes bothmethods practiced on the human body and also the foregoing activities.

As used herein, the following definitions may be useful in aiding theskilled practitioner in understanding the invention:

As used herein, the term “comprising” indicates the potential inclusionof other agents, elements, steps, or features, in addition to thosespecified.

As used herein, the term “25-hydroxyvitamin D” refers to one or more of25-hydroxyvitamin D₂, 25-hydroxyvitamin D₃, 25-hydroxyvitamin D₄,25-hydroxyvitamin D₅, 25-hydroxyvitamin D₇, analogs of the foregoing,and combinations thereof. It is specifically contemplated that in anyembodiment described herein, 25-hydroxyvitamin D can include25-hydroxyvitamin D₃, 25-hydroxyvitamin D₂, or a combination of25-hydroxyvitamin D₃ and 25-hydroxyvitamin D₂. For example, it isspecifically contemplated that in any embodiment described herein,25-hydroxyvitamin D can include 25-hydroxyvitamin D₃. Serum total25-hydroxyvitamin D refers to the total of all such 25-hydroxyvitamin Dforms measured by assay, unless a particular 25-hydroxyvitamin D form isreferred to.

As used herein, the term “1,25-dihydroxyvitamin D” refers to one or moreof 1,25-dihydroxyvitamin D₂, 1,25-dihydroxyvitamin D₃,1,25-dihydroxyvitamin D₄, 1,25-dihydroxyvitamin D₅,1,25-dihydroxyvitamin D₇, analogs of the foregoing, and combinationsthereof. For example, 1,25-dihydroxyvitamin D can include1,25-dihydroxyvitamin D₂, 1,25-dihydroxyvitamin D₃, or a combination of1,25-dihydroxyvitamin D₂ and 1,25-dihydroxyvitamin D₃. Serum total1,25-dihydroxyvitamin D will be understood to refer to the total of allsuch 1,25-dihydroxyvitamin D forms by assay, unless a reference is madeto a particular 1,25-dihydroxyvitamin D form.

As used herein, the term “cinacalcet” refers to the compoundN-[1-(R)-(-)-(1-naphthyl)ethyl]-3-[3-(trifluoromethyl)phenyl]-1-aminopropane(C₂₂H₂₂F₃N) or a salt thereof, including, but not limited to, acinacalcet salt comprising any one or more of acetate, adipate,alginate, citrate, aspartate, benzoate, benzenesulfonate, bisulfate,butyrate, camphorate, camphorsulfonate, digluconate,cyclopentanepropionate, dodecylsulfate, ethanesulfonate,glucoheptanoate, glycerophosphate, hemisulfate, heptanoate, hexanoate,fumarate, hydrochloride, hydrobromide, hydroiodide,2-hydroxy-ethanesulfonate, lactate, maleate, mandelate,methanesulfonate, nicotinate, 2-naphthalenesulfonate, oxalate, palmoate,pectinate, persulfate, 2-phenylpropionate, picrate, pivalate,propionate, salicylate, succinate, sulfate, tartrate, thiocyanate,tosylate, mesylate, and undecanoate, for example, cinacalcet HCl. Thecinacalcet or salt thereof can be in any form, including, for example,amorphous solids and/or crystalline solids, including polymorphs,pseudopolymorphs, and combinations thereof.

As used herein, the term “adjunctive therapy” refers to administrationof 25-hydroxyvitamin D to a patient who is (a) currently receiving; (b)has previously received; or (c) will receive, treatment with atherapeutic agent that is not 25-hydroxyvitamin D. In one aspect,adjunctive therapy refers to the administration of 25-hydroxyvitamin Dto a patient before administration with the therapeutic agent that isnot 25-hydroxyvitamin D. In another aspect, adjunctive therapy refers tothe administration of 25-hydroxyvitamin D to a patient concomitant withadministration with the therapeutic agent that is not 25-hydroxyvitaminD. In another aspect, adjunctive therapy refers to the administration of25-hydroxyvitamin D to a patient after administration with thetherapeutic agent that is not 25-hydroxyvitamin D. The therapeutic agentthat is not 25-hydroxyvitamin D is optionally an agent that increasesthe risk of hypocalcemia, such as cinacalcet, or an anticancer agent.

As used herein, the term “antiresorptive agent” refers to a compoundthat inhibits bone resorption, i.e., a “bone-sparing” agent. Examples ofantiresorptive agents include, but are not limited to, bisphosphonates(e.g., zoledronic acid, alendronate, risedronate, ibandronate,etidronate, and pamidronate), selective estrogen receptor modulators(e.g., raloxifene), calcitonin, hormones (e.g., estrogen), andmonoclonal antibodies (e.g., denosumab).

As used herein, the terms “co-administer” and “combination therapy”refer to administering an agent that increases the risk of hypocalcemia,such as cinacalcet, or an anticancer agent and 25-hydroxyvitamin D to asubject in a manner that permits the agents to exert their respectivepharmacological effects during an overlapping period of time and is aform of adjunctive therapy. The co-administered agent and25-hydroxyvitamin D can be administered by the same or different routes,and in the same or different compositions. The co-administered agent and25-hydroxyvitamin D can be administered at the same time, or atdifferent times during a course of treatment (e.g., on alternating daysor at different times in the same day). For example, it is contemplatedthat co-administration can include administration of both anantiresorptive agent or another agent that increases the risk ofhypocalcemia, such as cinacalcet, and a 25-hydroxyvitamin D compoundwithin six months or less of each other, or within three months or lessof each other, or within one month or less of each other, or within twoweeks or less of each other, or within one week or less of each other,or within two days or less of each other, or on the same day. A courseof the agent that increases the risk of hypocalcemia or an anticanceragent can include a relatively longer dose interval, e.g., every sixmonths, while 25-hydroxyvitamin D treatment can be on a shorterinterval, e.g., daily.

As used herein, the term “substantially constant” with respect to theserum or blood level of 25-hydroxyvitamin D means that the releaseprofile of any formulation administered as detailed herein should notinclude transient increases in total serum or blood levels of25-hydroxyvitamin D₃ or 25-hydroxyvitamin D₂ of greater thanapproximately 3 ng/mL after administration of a unit dose.

As used herein, the term “modified release” refers to any modificationof release from an immediate release profile and can include controlledor sustained release and/or delayed release characteristics. As usedherein, the term “controlled release” and “sustained release” are usedinterchangeably and refer to the release of the administered25-hydroxyvitamin D from a composition for an extended period of time,e.g., 4 to 24 hours or even longer.

As used herein, the term “rapid release” or “rapidly dissolving” refersto the release of more than 50% of an agent that increases the risk ofhypocalcemia from a pharmaceutical formulation within the first 30minutes after the formulation is administered to a patient.

As used herein, the term “Vitamin D toxicity” refers to the side effectsassociated with excessive administration of 25-hydoxyvitamin D andexcessively elevated 25-hydroxyvitamin D blood levels, including, butnot limited to, nausea, vomiting, polyuria, hypercalciuria,hypercalcemia and hyperphosphatemia.

As used herein, the term “hypocalcemia” refers to a condition wherein apatient has a corrected serum levels of calcium below about 8.3 mg/dL orbelow about 8.5 mg/dL. Severe hypocalcemia refers to a condition whereinthe patient has a corrected serum level of calcium below about 7 mg/dL.Normal and safe corrected serum levels of calcium for a human are in arange of about 8.3 to about 11.6 mg/dL. Corrected serum levels ofcalcium refer to values corrected for serum albumin less than 4.0 g/dL.The term “iatrogenic hypocalcemia” refers to hypocalcemia that occursfollowing treatment with a therapeutic agent, i.e., an agent thatincreases the risk of hypocalcemia. Examples of agents that increase therisk of hypocalcemia include, but are not limited to, antiresorptiveagents, anticonvulsant agents, corticosteroids, antihypercalcemiaagents, antimicrobial agents, and combinations thereof.

As used herein, the term “hypercalcemia” refers to a condition in apatient wherein the patient has corrected serum levels of calcium aboveabout 11.6 mg/dL.

As used herein, the term “hypophosphatemia” refers to a conditionwherein a patient has a serum phosphorous level below about 2.5 mg/dL.Normal and safe values for serum phosphorous in a human are in a rangeof about 2.5 mg/dL to about 4.5 mg/dL.

As used herein, the term “hyperphosphatemia” refers to a condition in apatient wherein the patient has serum phosphorous levels above about 4.5mg/dL.

As used herein, the term “supraphysiologic” in reference tointralumenal, intracellular and/or blood concentrations of25-hydroxyvitamin D refers to a combined concentration of25-hydroxyvitamin D forms during a 24-hour post-dose period which ismore than 5 ng/mL greater than the generally stable levels observed overthe course of the preceding 24-hour period by laboratory measurement.“Supraphysiologic” in reference to intralumenal, intracellular and/orblood concentrations of 1,25-dihydroxyvitamin D refers to a combinedconcentration of 1,25-dihydroxyvitamin D forms more than 5 pg/mL greaterthan the generally stable levels observed over the course of thepreceding 24-hour period by laboratory measurement.

As used herein, the term “Vitamin D insufficiency and deficiency” isgenerally defined in humans as having a serum 25-hydroxyvitamin D levelbelow 30 ng/mL (National Kidney Foundation guidelines, NKF, Am. J.Kidney Dis. 42:S1-S202 (2003), incorporated herein by reference).

As used herein, the term “granular form” refers to a mixture of solidparticles having a particle size at the 50^(th) percentile of a particlesize distribution of the mixture (granule D₅₀) in a range from about 50μm to about 150 μm, for example, about 50 μm, about 60 μm, about 70 μm,about 80 μm, about 90 μm, about 100 μm, about 110 μm, about 120 μm,about 130 μm, about 140 μm, or about 150 μm. The granule D₅₀ can bedetermined using methods known in the art such as sieve analysis, e.g.,as described in U.S. Pat. No. 7,829,595.

As used herein, the term “nonpareil” refers to a solid particle having,e.g., a spherical, spheroidal, cubic or cuboidal shape made from apharmaceutically acceptable material, e.g., sugar and/or starch. ,having a particle size in a range of 10 μm to 1000 μm.

It is specifically understood that any numerical value recited hereinincludes all values from the lower value to the upper value, i.e., allpossible combinations of numerical values between the lowest value andthe highest value enumerated are to be considered to be expressly statedin this application. For example, if a concentration range or abeneficial effect range is stated as 1% to 50%, it is intended thatvalues such as 2% to 40%, 10% to 30%, or 1% to 3%, etc., are expresslyenumerated in this specification. These are only examples of what isspecifically intended.

In one aspect, the disclosure provides methods of adjunctive therapyusing 25-hydroxyvitamin D is patients treated with an agent thatincreases the risk of hypocalcemia, such as cinacalcet, and/or ananticancer agent. The disclosed methods provide dual unexpected benefitswith continued regular administration over a prolonged period of time ofunsurpassed effectiveness in restoring blood 25-hydroxyvitamin D tooptimal levels and unsurpassed safety relative to currently availableformulations of Vitamin D or 25-hydroxyvitamin D. The methods of thepresent disclosure can include providing a gradual, sustained and directrelease of an effective amount of 25-hydroxyvitamin D, preferentially tocirculating DBP (rather than to chylomicrons), such that blood,intralumenal and intracellular 25-hydroxyvitamin D concentration spikes,and related unwanted catabolism are mitigated or eliminated.Administration of 25-hydroxyvitamin D according to the presentdisclosure enhances the intestinal absorption of calcium and reducesPTH-mediated bone resorption. This reduces the likelihood ofhypocalcemic events and at the same time, reduces the expression of PTH,thereby mitigating the metastatic impact on resorption of bone. Raising25-hydroxyvitamin levels in patients as described herein can stabilizeserum calcium levels and have an impact on bone microenvironment, cancerprogression, and skeletal related events.

Adjunctive therapy comprising 25-hydroxyvitamin D according to thepresent disclosure improves the efficacy of a co-administered agent thatincreases the risk of hypocalcemia (e.g., an antiresorptive agent or anantihypercalcemia agent such as cinacalcet) by one or more measures. Inone embodiment, co-administering an agent that increases the risk ofhypocalcemia and an effective amount of 25-hydroxyvitamin D is effect totreat or prevent iatrogenic hypocalcemia and SHPT. In anotherembodiment, co-administering an agent that increases the risk ofhypocalcemia and an effective amount of 25-hydroxyvitamin D is effectiveto increase bone mineral density. In another embodiment,co-administering an agent that increases the risk of hypocalcemia and aneffective amount of 25-hydroxyvitamin D is effect to decrease bone pain.In another embodiment, co-administering an agent that increases the riskof hypocalcemia and an effective amount of 25-hydroxyvitamin D iseffective to treat secondary hyperparathyroidism by lowering elevatedplasma PTH levels, optionally by at least 30%. In another embodiment,co-administering an agent that increases the risk of hypocalcemia and aneffective amount of 25-hydroxyvitamin D is effective to decrease theincidence or risk of hypocalcemia. In another embodiment,co-administering an agent that increases the risk of hypocalcemia and aneffective amount of 25-hydroxyvitamin D is effective to stabilize serumcalcium levels, optionally at a level in a range of 8.3 mg/dL and 11.6mg/dL, corrected for serum albumin. In another embodiment,co-administering an agent that increases the risk of hypocalcemia and aneffective amount of 25-hydroxyvitamin D is effective to increase bloodlevels of a bone formation marker. In another embodiment,co-administering an agent that increases the risk of hypocalcemia and aneffective amount of 25-hydroxyvitamin D is effective to decrease bloodlevels of a bone resorption marker. In another embodiment,co-administering an agent that increases the risk of hypocalcemia and aneffective amount of 25-hydroxyvitamin D is effective to delay the timeto the first post-treatment SRE. In another embodiment, co-administeringan agent that increases the risk of hypocalcemia and an effective amountof 25-hydroxyvitamin D is effective to delay the time to further bonemetastasis. In another embodiment, co-administering an agent thatincreases the risk of hypocalcemia and an effective amount of25-hydroxyvitamin D is effective to safely increase serum total25-hydroxyvitamin D levels to at least 30 ng/mL, optionally tosupraphysiologic levels. In another embodiment, co-administering anagent that increases the risk of hypocalcemia and an effective amount of25-hydroxyvitamin D is effective to safely increase serum total1,25-hydroxyvitamin D levels, optionally to supraphysiologic levels. Inanother embodiment, co-administering an agent that increases the risk ofhypocalcemia and an effective amount of 25-hydroxyvitamin D will beeffective to attenuate or halt cancer progression, e.g., by inhibitingthe proliferation and migration of cancer cells or maintaining ordecreasing tumor burden. In another embodiment, co-administering anagent that increases the risk of hypocalcemia and an effective amount of25-hydroxyvitamin D will be effective to treat hypercalcemia, e.g.,severe hypercalcemia, in a patient with parathyroid carcinoma or primaryhyperparathyroidism, optionally a patient who is unable to undergoparathyroidectomy.

In one embodiment, an effective amount of 25-hydroxyvitamin D isadministered to a patient that is receiving or has previously receivedtreatment with an agent that increases the risk of hypocalcemia. Forexample, in one embodiment, 25-hydroxyvitamin D is administeredfollowing administration of an agent that increases the risk ofhypocalcemia, e.g., an antiresorptive agent or antihypercalcemia agentsuch as cinacalcet. In another embodiment, 25-hydroxyvitamin D isadministered prophylactically to a patient before treatment with anagent that increases the risk of hypocalcemia is undertaken. In stillanother embodiment, 25-hydroxyvitamin D is co-administered, e.g., in asingle composition or separate compositions, with an agent thatincreases the risk of hypocalcemia. In various embodiments, the agentthat increases the risk of hypocalcemia is optionally selected from thegroup consisting of an antiresorptive agent, an anticonvulsant agent, acorticosteroid, an antihypercalcemia agent, an antimicrobial agent, andcombinations thereof. For example, in one embodiment, the agent thatincreases the risk of hypocalcemia is an antihypercalcemia agent, suchas cinacalcet. In another embodiment, the agent that increases the riskof hypocalcemia is an antiresorptive agent, optionally selected from thegroup consisting of bisphosphonates (e.g., zoledronic acid), RANKLinhibitors (e.g., denosumab), monoclonal antibodies (e.g., denosumab),and combinations thereof.

Another aspect of the present disclosure is treatment of cancer in apatient. Most cancer patients exhibit vitamin D insufficiency (i.e.,serum total 25-hydroxyvitamin D less than 30 ng/mL). Although there area number of possible causes, including diet and reduced exposure tosunlight, recent evidence suggests that accelerated vitamin D catabolismmay also be a contributor. Genome amplification at the 20q.13chromosomal locus that encodes CYP24A1 (Albertson et al. (2000) NatGenet 25, 144-146) has been identified in a number of tumor types(Krishnan et al., supra). Overexpression of CYP24A1 mRNA is reported ina wide variety of human cancers, including breast (Friedrich et al.(2003) Recent Results Cancer Res 164, 239-246), lung (Parise et al.(2006) Int J Cancer 119, 1819-1828) and colorectal, and in some cases,is linked to a poor prognosis and overall reduced survival (Mimori etal. (2004) Ann Oncol 15, 236-241). Overexpression of CYP24A1 increasesthe growth potential of tumor cells and lowers the responsiveness oftumors to the anti-cancer effects of endogenous calcitriol (Anderson etal. (2006) Cancer Chemother Pharmacol 57, 234-240; Friedrich et al.,supra). Higher levels of 25-hydroxyvitamin D may therefore be requiredto achieve vitamin D adequacy for normal cellular and physiologicalfunctions and to exert optimal antitumor effects. Administration of25-hydroxyvitamin D as described herein acts through activation of theVitamin D receptor pathway to maintain normal calcium homeostasis andcan thereby target a variety of tumor types.

Administration of 25-hydroxyvitamin D to a patient having cancer andadjunctive therapy comprising 25-hydroxyvitamin D and an anticanceragent is contemplated to have a therapeutic effect by one or moremeasures. In one embodiment, administering an effective amount of25-hydroxyvitamin D, optionally with an anticancer agent and/or agentthat increases the risk of hypocalcemia, to the patient is effective totreat cancer, e.g., by inhibiting the proliferation and migration ofcancer cells. In another embodiment, administering an effective amountof 25-hydroxyvitamin D, optionally with an anticancer agent and/or agentthat increases the risk of hypocalcemia, is effective to maintain ordecrease the patient's tumor burden. In another embodiment,administering an effective amount of 25-hydroxyvitamin D, optionallywith an anticancer agent and/or agent that increases the risk ofhypocalcemia, is effective to mitigate the progression of cancer in thebone. In another embodiment, administering an effective amount of25-hydroxyvitamin D, optionally with an anticancer agent and/or agentthat increases the risk of hypocalcemia, is effective to slow tumorgrowth and/or metastasis and increase the time to thefirst-post-treatment SRE in a patient with a bone tumor, optionally abone metastasis from a solid tumor. In another embodiment,administration of a prophylactic and continuing course of an effectiveamount of 25-hydroxyvitamin D to the patient to stabilize serum25-hydroxyvitamin D and calcium levels followed by treatment with anagent known to increase the risk of iatrogenic hypocalcemia is effectiveto prevent or treat the iatrogenic hypocalcemia.

In any of the methods disclosed herein, administration of25-hydroxyvitamin D to a patient, e.g., a patient treated with an agentthat increases the risk of hypocalcemia or an anticancer agent, asdescribed can be characterized by one or more measures described below,individually or in combination. In one aspect, the amount of25-hydroxyvitamin D or combination therapy comprising 25-hydroxyvitaminD and an agent that increases the risk of hypocalcemia administered iseffective to restore or maintain the patient's corrected serum calciumlevel to at least about 8.0 mg/dL, optionally in a range of about 8.3mg/dL to about 11.6 mg/dL. In another aspect, the amount of25-hydroxyvitamin D or combination therapy comprising 25-hydroxyvitaminD and an agent that increases the risk of hypocalcemia administered canbe effective to restore or maintain the patient's corrected serumcalcium level to at least about 8.3 mg/dL, 8.5 mg/dL, at least about 9.0mg/dL, at least about 9.5 mg/dL, at least about 10 mg/dL, at least about10.5 mg/dL, or at least about 11.0 mg/dL, optionally in a range of about8.5 mg/dL to about 11.0 mg/dL, about 8.3 mg/dL to about 10.2 mg/dL,about 8.3 mg/dL to about 11.0 mg/dL, or about 8.5 mg/dL to about 10.2mg/dL, for example.

In another aspect, the amount of 25-hydroxyvitamin D or combinationtherapy comprising 25-hydroxyvitamin D and an agent that increases therisk of hypocalcemia administered can be effective to safely increasethe patient's serum level of 25-hydroxyvitamin D to at least about 30ng/mL, optionally in a range of about 30 ng/mL to about 100 ng/mL, about35 ng/mL to about 90 ng/mL, about 40 ng/mL to about 100 ng/mL, or about50 ng/mL to about 100 ng/mL. In another aspect, the amount of25-hydroxyvitamin D or combination therapy comprising 25-hydroxyvitaminD and an agent that increases the risk of hypocalcemia administered canbe effective to safely increase the patient's serum level of25-hydroxyvitamin D to at least about 35 ng/mL, at least about 40 ng/mL,at least about 50 ng/mL, at least about 60 ng/mL, at least about 70ng/mL, at least about 80 ng/mL, at least about 90 ng/mL, at least about100 ng/mL, at least about 150 ng/mL, at least about 200 ng/mL, at leastabout 250 ng/mL, or at least about 300 ng/mL.

In another aspect, the amount of 25-hydroxyvitamin D or combinationtherapy comprising 25-hydroxyvitamin D and an agent that increases therisk of hypocalcemia administered can be effective to decrease thepatient's serum parathyroid hormone level, optionally by at least about10%, at least about 20%, at least about 30%, at least about 40%, or atleast about 50%. In another aspect, the amount of 25-hydroxyvitamin D orcombination therapy comprising 25-hydroxyvitamin D and an agent thatincreases the risk of hypocalcemia administered can be effective todecrease the patient's serum parathyroid hormone related peptide (PTHrP)level, optionally by at least about 10%, at least about 20%, at leastabout 30%, at least about 40%, or at least about 50%.

In another aspect, the amount of 25-hydroxyvitamin D or combinationtherapy comprising 25-hydroxyvitamin D and an agent that increases therisk of hypocalcemia administered can be effective to safely increasethe patient's serum level of 1,25-dihydroxyvitamin D, optionally to atleast about 50 pg/mL, at least about 60 pg/mL, at least about 70 pg/mL,at least about 80 pg/mL, at least about 90 pg/mL, or at least about 100pg/mL.

In another aspect, the amount of 25-hydroxyvitamin D or combinationtherapy comprising 25-hydroxyvitamin D and an agent that increases therisk of hypocalcemia administered can be effective to achieve ormaintain safe serum phosphorous levels, and prevent hypophosphatemia. Inanother aspect, the amount of 25-hydroxyvitamin D or combination therapycomprising 25-hydroxyvitamin D and an agent that increases the risk ofhypocalcemia administered can be effective to achieve or maintain serumphosphorus levels above about 2.5 mg/dL, above about 3.0 mg/dL, aboveabout 3.5 mg/dL, above about 4.0 mg/dL, or above about 4.5 mg/dL,optionally in a range between about 2.5 mg/dL and about 4.5 mg/dL.

In another aspect, the amount of 25-hydroxyvitamin D or combinationtherapy comprising 25-hydroxyvitamin D and an agent that increases therisk of hypocalcemia administered can be effective to have a positiveeffect on the patient's serum level of a marker of bone formationcompared to no treatment or treatment with an antiresorptive agentalone. For example, the amount of 25-hydroxyvitamin D or combinationtherapy comprising 25-hydroxyvitamin D and an agent that increases therisk of hypocalcemia administered can be effective to increase thepatient's serum level of a marker of bone formation, e.g., bonemorphogenetic protein or osteocalcin, by at least about 10%, at leastabout 20%, at least about 30%, at least about 40%, or at least about50%, compared to no treatment or treatment with an antiresorptive agentalone. In another aspect, the amount of 25-hydroxyvitamin D orcombination therapy comprising 25-hydroxyvitamin D and an agent thatincreases the risk of hypocalcemia administered can be effective todecrease the patient's serum level of a marker of bone resorption,optionally by at least 10%, at least 20%, at least about 30%, at leastabout 40%, or at least about 50%, compared to no treatment levels ortreatment with an antiresorptive agent alone. In another aspect, theamount of 25-hydroxyvitamin D or combination therapy comprising25-hydroxyvitamin D and an agent that increases the risk of hypocalcemiaadministered can effective to mitigate the increase in the patient'sserum level of a marker of bone resorption compared to no treatment ortreatment with an antiresorptive agent alone. In various embodiments,the marker of bone resorption is selected from the group consisting ofPTHrP, FGF23, NTX, CTX, TRAC-5b, and combinations thereof.

In another aspect, the amount of 25-hydroxyvitamin D or combinationtherapy comprising 25-hydroxyvitamin D and an agent that increases therisk of hypocalcemia administered can be effective to decrease orincrease the patient's serum level of an immune meditating cytokine,e.g. C-reactive protein (CRP), interleukin12, or interleukin 10,optionally by at least about 10%, at least about 20%, at least about30%, at least 40%, or at least about 50%. In another aspect, the amountof 25-hydroxyvitamin D can be effective to increase the spotcalcium/creatinine (Ca/Cr) ratio.

In another aspect, the amount of 25-hydroxyvitamin D or combinationtherapy comprising 25-hydroxyvitamin D and an agent that increases therisk of hypocalcemia administered can be effective to maintain ordecrease the patient's tumor burden. Tumor burden may be measured usingassays known in the art, e.g., radiography, computed tomography (CT), ormagnetic resonance imaging (MRI). Tumor burden may also be assessed bymeasuring one or more markers of tumor burden. In another aspect, theamount of 25-hydroxyvitamin D or combination therapy comprising25-hydroxyvitamin D and an agent that increases the risk of hypocalcemiaadministered can be effective to decrease the patient's serum level of amarker of tumor burden, optionally by at least about 10%, at least about20%, at least about 30%, at least about 40%, or at least about 50%,compared to no treatment or treatment with an anticancer agent and/or anagent that increases the risk of hypocalcemia alone. In another aspect,the amount of 25-hydroxyvitamin D or combination therapy comprising25-hydroxyvitamin D and an agent that increases the risk of hypocalcemiaadministered can be effective to mitigate the increase in the patient'stumor burden or serum level of a marker of tumor burden, compared to notreatment or treatment with an anticancer agent and/or agent thatincreases the risk of hypocalcemia only. In embodiments, the marker oftumor burden can be optionally selected from the group consisting ofCEA, CA 125, CA15-3, CA 27-29, prostate specific antigen (PSA), andcombinations thereof.

In one aspect, combination therapy comprising an effective amount of25-hydroxyvitamin D and an effective amount of an agent that increasesthe risk of hypocalcemia such as cinacalcet can be effective to treatsecondary hyperparathyroidism in Chronic Kidney Disease, optionally in apatient on dialysis, wherein said effective amount of the agent thatincreases the risk of hypocalcemia is a reduced dose compared to theeffective dose of the agent that increases the risk of hypocalcemia inthe absence of said 25-hydroxyvitamin D administration. In anotheraspect, combination therapy comprising an effective amount of25-hydroxyvitamin D and an effective amount of an agent that increasesthe risk of hypocalcemia such as cinacalcet can be effective to treathypercalcemia, e.g., in a patient having parathyroid carcinoma orprimary hyperparathyroidism, wherein said effective amount of the agentthat increases the risk of hypocalcemia is a reduced dose compared tothe effective dose of the agent that increases the risk of hypocalcemiain the absence of said 25-hydroxyvitamin D administration. For example,the effective amount of the agent that increases the risk ofhypocalcemia co-administered with 25-hydroxyvitamin D can be about 5%less, about 10% less, about 15% less, about 20% less, about 25% less,about 30% less, about 35% less, about 40% less, about 45% less, or about50% less, than the effective dose of the agent that increases the riskof hypocalcemia in the absence of said 25-hydroxyvitamin Dco-administration. For example, in one embodiment, the effective amountof the agent that increases the risk of hypocalcemia co-administeredwith 25-hydroxyvitamin D is cinacalcet or a salt thereof in an amount ofless than 360 mg daily, for example in a range of 30 mg to 90 mg, 30 mgto 60 mg, 20 mg to 60 mg, or 20 mg to 25 mg, administered once, twice,three, or four times daily.

In one class of embodiments, the effective amount of 25-hydroxyvitamin Dis co-administered with an agent that increases the risk of hypocalcemiaand/or an anticancer agent. In one embodiment, 25-hydroxyvitamin D isco-administered with cinacalcet or a salt thereof, optionally in asingle formulation, e.g., a capsule comprising both agents.

The present disclosure also provides a kit comprising (a)25-hydroxyvitamin D, (b) an agent that increases the risk ofhypocalcemia and/or an anticancer agent, and (c) instructions forco-administering effective amounts of (a) and (b) to a patient in needthereof. The indications and usage of the agent(s) co-administered with25-hydroxyvitamin D according to the present methods are notparticularly limited, and can be equivalent to those already taught inthe literature.

The methods of the present disclosure are suitable for treating patientshaving a condition responsive to administration of 25-hydroxyvitamin Das described. In one type of embodiment, the patient has osteoporosis.In another type of embodiment, the patient has hungry bone syndrome. Inanother type of embodiment, the patient has impaired renal function,e.g., a patient having Chronic Kidney Disease (CKD) Stage 1, 2, 3, 4, or5. In one embodiment, the patient is receiving dialysis. In anotherembodiment, the patient has CKD, but is not on dialysis.

In another type of embodiment, the patient has cancer, optionally acancer selected from the group consisting of bone cancer, bladdercancer, breast cancer, colon cancer, endometrial cancer, kidney cancer,leukemia, lung cancer, lymphoma, pancreatic cancer, parathyroid cancer,prostate cancer, skin cancer, thyroid cancer, and metastatic formsthereof. In one embodiment, the patient has cancer and a bone tumor,i.e., a bone metastasis from a solid tumor. For example, the patient mayhave metastatic bone cancer, metastatic prostate cancer, metastatic lungcancer, and/or metastatic breast cancer.

Optionally, the patient has cancer and is receiving, has previouslyreceived, or will receive, treatment with an anticancer agent. Exemplaryclasses of anticancer agents include, but are not limited to, anaromatase inhibitor; an anti-estrogen; an anti-androgen; a gonadorelinagonist; a topoisomerase I inhibitor; a topoisomerase II inhibitor; amicrotubule active agent; an alkylating agent; a retinoid, a carotenoid,or a tocopherol; a cyclooxygenase inhibitor; an MMP inhibitor; a mTORinhibitor; an antimetabolite; a platin compound; a methionineaminopeptidase inhibitor; a bisphosphonate; an antiproliferativeantibody; a heparanase inhibitor; an inhibitor of Ras oncogenicisoforms; a telomerase inhibitor; a proteasome inhibitor; a Flt-3inhibitor; an Hsp90 inhibitor; a kinesin spindle protein inhibitor; aMEK inhibitor; an antitumor antibiotic; a nitrosourea, a compoundtargeting/decreasing protein or lipid kinase activity, a compoundtargeting/decreasing protein or lipid phosphatase activity, anantiangiogenic compound, and combinations thereof. In various types ofembodiments, the patient can be treated with an anticancer agentselected from the group consisting of azacitidine, axathioprine,bevacizumab, bleomycin, capecitabine, carboplatin, chlorabucil,cisplatin, cyclophosphamide, cytarabine, daunorubicin, docetaxel,doxifluridine, doxorubicin, epirubicin, etoposide, fluorouracil,gemcitabine, herceptin, idarubicin, mechlorethamine, melphalan,mercaptopurine, methotrexate, mitoxantrone, oxaliplatin, paclitaxel,tafluposide, teniposide, tioguanine, retinoic acid, valrubicin,vinblastine, vincristine, vindesine, vinorelbine, receptor tyrosinekinase inhibitors, and combinations thereof.

Optionally, the patient having a condition described above to be treatedwith 25-hydroxyvitamin D is receiving, has previously received, or willreceive, treatment with an agent that increases the risk ofhypocalcemia, optionally an agent selected from the group consisting ofan antiresorptive agent, an anticonvulsant agent, a corticosteroid, anantihypercalcemia agent, an antimicrobial agent, and combinationsthereof. In one type of embodiment, the agent that increases the risk ofhypocalcemia is an antihypercalcemia agent, optionally theantihypercalcemia agent cinacalcet. In another type of embodiment, theagent that increases the risk of hypocalcemia is an antiresorptiveagent, optionally selected from the group consisting of bisphosphonates,selective estrogen receptor modulators, calcitonin, hormones, andmonoclonal antibodies. In one type of embodiment, the antiresorptiveagent comprises a RANKL inhibitor, optionally the RANKL inhibitordenosumab. In another type of embodiment, the antiresorptive agentcomprises a bisphosphonate, optionally the bisphosphonate zoledronicacid. Optionally, a patient having cancer is receiving, has previouslyreceived, or will receive, treatment with an agent that increases therisk of hypocalcemia and an anticancer agent.

For each of the foregoing measures, it is contemplated that adjunctivetherapy with 25-hydroxyvitamin D will achieve such increases, decreases,and/or delays to a greater degree compared to administering the agentthat increases the risk of hypocalcemia, e.g., cinacalcet, and/oranticancer agent alone. In another aspect, it is contemplated that theadjunctive therapy with 25-hydroxyvitamin D will achieve such increases,decreases, and/or delays to a greater degree compared toco-administering the agent that increases the risk of hypocalcemia withcholecalciferol, optionally with an anticancer agent. It is contemplatedthat the adjunctive therapy with 25-hydroxyvitamin D will achieve suchincreases, decreases, and/or delays to a greater degree compared toco-administering the agent that increases the risk of hypocalcemia withergocalciferol, optionally with an anticancer agent. It is alsocontemplated that adjunctive therapy with 25-hydroxyvitamin D willmitigate, i.e., lessen the severity of, undesirable effect compared toadministering the agent that increases the risk of hypocalcemia and/oranticancer agent alone or the antiresorptive agent with cholecalciferolor ergocalciferol, optionally with an anticancer agent. Examples ofundesired effects include, but are not limited to, an increase ordecrease of serum calcium or phosphorous to a level outside the normalrange, a decrease in blood levels of a bone formation marker, anincrease in blood levels of a bone resorption marker, and an increase intumor burden (e.g., an increase in a marker of tumor progression).

The present disclosure also contemplates compositions comprising oral orintravenous formulations of 25-hydroxyvitamin D and related methods ofadministration. Such compositions and related methods of administrationcan be selected to have one or more features including increasing bloodlevels of 25-hydroxyvitamin D without the potential first-pass effectsof 25-hydroxyvitamin D prohormones in the duodenum; withoutsupraphysiological surges in intralumenal, intracellular and bloodlevels of 25-hydroxyvitamin D and their consequences; without causingsubstantially increased catabolism of the administered 25-hydroxyvitaminD; and without causing serious side effects associated with Vitamin Dsupplementation, namely Vitamin D toxicity.

In one type of embodiment, modified release compositions intended fororal administration in accordance with the present invention aredesigned to contain a dosage of 25-hydroxyvitamin D (e.g.25-hydroxyvitamin D₃, or a combination of 25-hydroxyvitamin D₂ and25-hydroxyvitamin D₃) of 1 to 1000 mcg per unit dose, or 1 to 500 mcgper unit dose or 1 to 100 mcg per dose, or 1 to 50 mcg per dose, or 10to 40 mcg per dose, for example, 30 mcg, 60 mcg, 90 mcg, 100 mcg, 200mcg, 300 mcg, 400 mcg, 500 mcg, 600 mcg, 700 mcg, 800 mcg, 900 mcg, or1000 mcg 25-hydroxyvitamin D per unit dose, and are prepared in such amanner as to effect controlled or substantially constant release of the25-hydroxyvitamin D into the gastrointestinal tract of a subject over anextended period of time. In one embodiment, the 25-hydroxyvitamin D is25-hydroxyvitamin D₃. In another embodiment, the 25-hydroxyvitamin D isa combination of 25-hydroxyvitamin D₃ and 25-hydroxy vitamin D₂ and areuseful in supporting both the Vitamin D₃ and Vitamin D₂ endocrinesystems. Currently available oral Vitamin D supplements and thepreviously marketed oral formulation of 25-hydroxyvitamin D₃ havesupported just one or the other system. In one type of embodiment, therelease can be in the ileum or later, for example in the colon. Inanother type of embodiment, the composition can result in asubstantially increased absorption of 25-hydroxyvitamin D via transporton DBP and decreased absorption via transport in chylomicrons. Inanother type of embodiment, the composition can result in maintenance ofsubstantially constant blood levels of 25-hydroxyvitamin D during the24-hour post-dosing period. Examples of modified release compositions of25-hydroxyvitamin D are described in U.S. Pat. Nos. 8,207,149,8,361,488, and 8,426,391, and U.S. patent application Ser. No.14/213,285, incorporated herein by reference.

In one aspect, a composition of the present disclosure comprising25-hydroxyvitamin D further comprises an agent that increases the riskof hypocalcemia. In one embodiment, a pharmaceutical formulation fororal administration of the present disclosure comprises (a) a25-hydroxyvitamin D compound (e.g., 25-hydroxyvitamin D₃ and/or25-hydroxyvitamin D₂) and (b) and agent that increases the risk ofhypocalcemia (e.g., cinacalcet or cinacalcet HCl). In one embodiment,the pharmaceutical formulation comprises (a) and (b) in a singlecapsule, e.g., a hard shell or soft capsule, optionally a multi-layeredor multi-chambered capsule. For example, in one embodiment, apharmaceutical formulation of the present disclosure comprises a firstregion comprising the 25-hydroxyvitamin D compound and a second regioncomprising the agent that increases the risk of hypocalcemia, forexample, in a multi-layered composition having a 25-hydroxyvitamin Dcore and an outer layer or surface coating comprising the agent thatincreases the risk of hypocalcemia or comprising the agent thatincreases the risk of hypocalcemia disposed in a first capsule shell andthe 25-hydroxyvitamin D compound disposed in second capsule shell, thesecond capsule shell being disposed within the first capsule shell. Inanother embodiment, the pharmaceutical formulation comprises amulti-chambered composition comprising adjacent first and second, e.g.,tandem, regions/chambers. In other embodiments, a pharmaceuticalformulation comprises particles comprising the agent that increases therisk of hypocalcemia, e.g., cinacalcet, in granular form, for example,as described in U.S. Pat. No. 7,829,595, incorporated herein byreference, or nonpareils coated with the agent that increases the riskof hypocalcemia. The particles comprising the agent that increases therisk of hypocalcemia can be in a second region separate from a firstregion comprising 25-hydroxyvitamin D, or dispersed within a non-aqueoussolution comprising 25-hydroxyvitamin D disposed within a capsule. Invarious embodiments, a composition of the present disclosure comprises25-hydroxyvitamin D in an amount between 1 mcg to 1000 mcg per unitdose, or 1 mcg to 500 mcg per unit dose, or 1 mcg to 100 mcg per dose,or 1 mcg to 50 mcg per dose, or 10 mcg to 40 mcg per dose, or 100 mcg to300 mcg, for example, 30 mcg, 60 mcg, 90 mcg, 100 mcg, 200 mcg, 300 mcg,400 mcg, 500 mcg, 600 mcg, 700 mcg, 800 mcg, 900 mcg, or 1000 mcg25-hydroxyvitamin D per unit dose and cinacalcet in an amount between 1mg to 500 mg per unit dose, or 1 mg to 100 mg per unit dose, or 100 mgto 400 mg per dose, or 1 mg to 50 mg per dose, or 10 mg to 40 mg perdose, for example, 10 mg, 15 mg, 20 mg, 25 mg, 30 mg, 60 mg, 90 mg, 100mg, 150 mg, 200 mg, 250 mg, 300 mg, 350 mg, 400 mg, 450 mg, or 500 mgcinacalcet per unit dose. In any of the embodiments of the presentdisclosure, a pharmaceutical formulation optionally comprises (a)25-hydroxyvitamin D and (b) an agent that increases the risk ofhypocalcemia in an amount that is bioequivalent to a dosage describedherein.

A pharmaceutical formulation of the present disclosure optionallycomprises 25-hydroxyvitamin D in a modified release formulation asdescribed herein and/or an agent that increases the risk ofhypocalcemia, e.g. cinacalcet, in an immediate release formulation. Forexample, in one embodiment, the composition comprises a modified releasecomposition of 25-hydroxyvitamin D as described herein or in U.S. Pat.Nos. 8,207,149, 8,361,488, and 8,426,391, and U.S. patent applicationSer. No. 14/213,285, incorporated herein by reference, and/or cinacalcetin an immediate release formulation such as a rapidly dissolvingformulation as described in U.S. Pat. No. 7,829,595, incorporated hereinby reference. In one embodiment, a pharmaceutical formulation comprisesa core region comprising 25-hydroxyvitamin D in a modified releaseformulation, and an outer layer, e.g., a surface coating, comprisingcinacalcet in an immediate release formulation such as a rapidlydissolving formulation. In another embodiment, a pharmaceuticalformulation comprises a first region comprising 25-hydroxyvitamin D in amodified release formulation and particles comprising cinacalcetdispersed within the first region or within a second region. In one typeof embodiment, the co-formulated dosage form with 25-hydroxyvitamin Dand cinacalcet HCl will deliver an amount of cinacalcet HCl that isbioequivalent to SENSIPAR, on a mg-per-mg basis.

In various embodiments, a pharmaceutical formulation of the presentdisclosure comprises a region (e.g., a layer, a chamber, a granule, or acoating on a capsule or nonpareil) comprising cinacalcet in an immediaterelease formulation further comprising one or more of a diluent, abinder, a disintegrant, and combinations thereof. Examples ofpharmaceutically acceptable diluents include, but are not limited to,starch, microcrystalline cellulose, dicalcium phosphate, lactose,sorbitol, mannitol, sucrose, methyl dextrins, and combinations thereof.Examples of binders include, but are not limited to, povidone,hydroxypropyl methylcellulose, dihydroxy propylcellulose, sodiumcarboxylmethylcellulose, gelatin, acacia, tragacanth, alginic acid,cellulose, methyl cellulose, ethyl cellulose, hydroxypropyl cellulose,polyethylene glycol, polyvinyl alcohol, polymethacrylate,polyvinylcaprolactam, and combinations thereof. Examples ofdisintegrants include, but are not limited to, crospovidone, sodiumstarch glycolate, croscarmellose sodium, croscarmellose, sodium starchglycolate, cross linked cellulose, cross linked polymers, cross linkedstarches, and combinations thereof.

In one embodiment, a pharmaceutical formulation comprises a regioncomprising cinacalcet or a salt thereof in an immediate releaseformulation comprising from about 10% to about 40% by weight ofcinacalcet or a salt thereof, from about 45% to about 85% by weight ofat least one diluent, and from about 1% to about 10% by weight of atleast one disintegrant, optionally further comprising from about 1% toabout 5% by weight of at least one binder, wherein the percentage byweight is relative to the total weight of the region.

For example, in one embodiment, a composition according to the presentdisclosure comprises a region comprising cinacalcet or a salt thereof inan immediate release formulation comprising from about 10% to about 40%by weight of cinacalcet or a salt thereof, from about 40% to about 75%by weight of microcrystalline cellulose, from about 1% to about 5% byweight povidone, from about 5% to about 10% by weight of starch, andfrom about 1% to about 10% by weight of crosprovidone, optionallyfurther comprising from about 0.05% to about 1.5% by weight of colloidalsilicon dioxide and from about 0.05% to about 1.5% by weight ofmagnesium stearate, wherein the percentage by weight is relative to thetotal weight of the region.

In another embodiment, a composition according to the present disclosurecomprises a region comprising cinacalcet or a salt thereof in animmediate release formulation comprising from about 10% to about 40% byweight of cinacalcet or a salt thereof, from about 40% to about 75% byweight of microcrystalline cellulose, from about 1% to about 5% byweight povidone, and from about 5% to about 35% by weight of starch,optionally further comprising from about 0.05% to about 1.5% by weightof colloidal silicon dioxide and from about 0.05% to about 1.5% byweight of magnesium stearate, wherein the percentage by weight isrelative to the total weight of the region.

In another embodiment, a composition according to the present disclosurecomprises a region comprising cinacalcet or a salt thereof in animmediate release formulation comprising from about 10% to about 40% byweight of cinacalcet or a salt thereof, from about 40% to about 75% byweight of microcrystalline cellulose, from about 15% to about 50% byweight of starch, and from about 1% to about 10% by weight of adisintegrant selected from croscarmellose, sodium starch glycolate,cross linked cellulose, cross linked polymers, cross linked starches,and combinations thereof, optionally further comprising from about 0.05%to about 1.5% by weight of colloidal silicon dioxide and from about0.05% to about 1.5% by weight of magnesium stearate, wherein thepercentage by weight is relative to the total weight of the region.

In another embodiment, a composition according to the present disclosurecomprises a region comprising cinacalcet or a salt thereof in animmediate release formulation comprising from about 10% to about 40% byweight of cinacalcet or a salt thereof, from about 40% to about 75% byweight of microcrystalline cellulose, from about 1% to about 5% byweight of povidone, and from about 1% to about 10% by weight of adisintegrant selected from croscarmellose, sodium starch glycolate,cross linked cellulose, cross linked polymers, cross linked starches,and combinations thereof, optionally further comprising from about 0.05%to about 1.5% by weight of colloidal silicon dioxide and from about0.05% to about 1.5% by weight of magnesium stearate, wherein thepercentage by weight is relative to the total weight of the region.

In another embodiment, a composition according to the present disclosurecomprises a region comprising cinacalcet or a salt thereof in animmediate release formulation comprising from about 10% to about 40% byweight of cinacalcet or a salt thereof, from about 40% to about 75% byweight of microcrystalline cellulose, from about 1% to about 5% byweight of a binder selected from the group consisting of gelatin,acacia, tragacanth, alginic acid, cellulose, methyl cellulose, ethylcellulose, HPMC, HPC, sodium carboxy methyl cellulose, PEG, PVA,polymethacrylate, polyvinylcaprolactam, and combinations thereof, fromabout 5% to about 35% by weight of starch, and from about 1% to about10% by weight of crospovidone, optionally further comprising from about0.05% to about 1.5% by weight of colloidal silicon dioxide and fromabout 0.05% to about 1.5% by weight of magnesium stearate, wherein thepercentage by weight is relative to the total weight of the region.

In one embodiment, the pharmaceutical formulation can be characterizedby dissolution release profile providing a release of 25-hydroxyvitaminD of less than 30% at 2 hours, greater than 45% at 6 hours, and greaterthan 80% at 12 hours, and further optionally less than 60% at 6 hours.In another type of embodiment, the formulation can be characterized byan in vitro dissolution profile providing release of 25-hydroxyvitamin Dof less than 30% at 100 to 140 minutes, greater than 45% at 5 to 7hours, and greater than 80% at 11 to 13 hours. In another embodiment,the composition can be characterized by an in vitro dissolution profileproviding release of 25-hydroxyvitamin D of less than 30% at 2 hours,greater than 45% at 6 hours, and greater than 80% at 12 hours. In thesetypes of embodiments, optionally the release of vitamin D compound at 5to 7 hours is less than 60%, or at 6 hours is less than 60%.

In another type of embodiment, the composition can be characterized byan in vitro dissolution profile providing release of 25-hydroxyvitamin Dof about 20% to about 40% at 2 hours, at least 35% at 6 hours, and atleast 70% at 12 hours. In another embodiment, the formulation can becharacterized by an in vitro dissolution profile providing release of25-hydroxyvitamin D compound of about 25% to about 35% at 2 hours, atleast 40% at 6 hours, and at least 75% at 12 hours. In theseembodiments, optionally the release of 25-hydroxyvitamin D is 75% orless at 6 hours, or 65% or less at 6 hours, or 60% or less at 6 hours,for example.

In any of the embodiments described herein, the composition can becharacterized by an in vitro dissolution profile providing release ofcinacalcet of about 50% to about 100% at 30 minutes or less. Optionally,the release of cinacalcet is at least 80% at 15 minutes, at least 90% at30 minutes, at least 97% at 45 minutes, or at least 98% at 60 minutes.For example, in some embodiments, the release of cinacalcet is at least85%, at least 90%, at least 95%, or at least 98% at 15 minutes.

The release of 25-hydroxyvitamin D or cinacalcet can be measured using asuitable in vitro dissolution method, such as one of the methods alreadyknown in the art. Any of the dissolution studies described in the UnitedStates Pharmacopeia, USP 29-NF 24, Dissolution <711>physical tests anddeterminations, United States Pharmacopeial Convention, Inc., Rockville,Md., 2006, pp. 2673-2682.; European Pharmacopoeia 2.9.3 Dissolution Testfor Solid Dosage Forms, or the Japanese Pharmacopoeia 6.10 DissolutionTest, can be used to determine the in vitro dissolution profile inaccordance with the present disclosure.

In one type of embodiment, the 25-hydroxyvitamin D is administeredorally. For example, the 25-hydroxyvitamin D can be administered in anoral modified release formulation. In the alternative, the25-hydroxyvitamin D can be administered in an oral immediate releaseformulation in multiple daily doses in order to produce apharmacokinetic profile of serum 25-hydroxyvitamin D that is similar tothat achieved by an oral modified or sustained release formulation.

The preparation of a modified release form of 25-hydroxyvitamin Dsuitable for oral administration can be carried out according to manydifferent techniques. For example, one or more 25-hydroxyvitamin Dcompounds can be dispersed within a matrix, i.e., a unique mixture ofrate controlling constituents and excipients in carefully selectedratios within the matrix, and optionally encased with a coatingmaterial. In another alternative, various coating techniques can beutilized to control the rate and/or the site of the release of the25-hydroxyvitamin D from the pharmaceutical formulation. For example,the dissolution of the coating may be triggered by the pH of thesurrounding media, and the resulting gradual dissolution of the coatingover time exposes the matrix to the fluid of the local environment. Inone type of embodiment, after the coating becomes permeable,25-hydroxyvitamin D diffuses from the outer surface of the matrix. Whenthis surface becomes exhausted or depleted of 25-hydroxyvitamin D, theunderlying stores begin to be depleted by diffusion through thedisintegrating matrix to the external solution. In another type ofembodiment, release of 25-hydroxyvitamin D is by gradual disintegrationor erosion of the matrix, e.g., via solubility of one or more componentsof the matrix and/or by lack of physical integrity.

In one aspect, a formulation in accordance with the present inventionprovides one or more 25-hydroxyvitamin D compounds within a matrix thatreleasably binds the ingredients for sustained release, e.g., whenexposed to the contents of the ileum and/or colon.

Optionally, the 25-hydroxyvitamin D-containing matrix can be suitablycovered with a coating that is resistant to disintegration in gastricjuices. The coated modified release formulation of 25-hydroxyvitamin Dis then administered orally to subjects, e.g., animals or humanpatients. As the formulation travels through the proximal portion of thesmall intestine, the enteric coating becomes progressively morepermeable but, in a suitable embodiment, it provides a persistingstructural framework around the 25-hydroxyvitamin D-containing matrix.The 25-hydroxyvitamin D-containing matrix becomes significantly exposedto intestinal fluids in the ileum through the permeable overcoating, andthe 25-hydroxyvitamin hydroxyvitamin D is then gradually released bysimple diffusion and/or slow disintegration of the matrix.

Once released into the lumen of the ileum, the 25-hydroxyvitamin D isabsorbed into the lymphatic system or into the portal bloodstream, whereit is bound to and transported by the DBP. In this embodiment, the25-hydroxyvitamin D is primarily absorbed at a point beyond the duodenumand jejunum. These proximal portions of the small intestine can respondto high intralumenal levels of 25-hydroxyvitamin D and in the process,can catabolize significant quantities of the 25-hydroxyvitamin D. Bysubstantially delaying 25-hydroxyvitamin D release until the ileumand/or colon, the pharmaceutical composition described herein virtuallyeliminates these potential first-pass effects in the proximal intestineand reduces unwanted catabolism. Significant catabolism of administered25-hydroxyvitamin D prior to absorption into the bloodstreamsignificantly lowers its bioavailability. Elimination of first-passeffects reduces the risk of Vitamin D toxicity. Substantially delayedrelease of 25-hydroxyvitamin D (i.e., beyond the duodenum and jejunum)markedly decreases the amount of 25-hydroxyvitamin D that isincorporated and absorbed from the small intestine via chylomicrons(since chylomicron formation and absorption occurs primarily in thejejunum) and correspondingly increases the amount of 25-hydroxyvitamin Dthat is absorbed directly through the intestinal wall and onto DBPcirculating in lymph or portal blood.

In one embodiment of the invention, a controlled release oralformulation of 25-hydroxyvitamin D is prepared generally according tothe following procedure. A sufficient quantity of 25-hydroxyvitamin D iscompletely dissolved in a minimal volume of USP-grade absolute ethanol(or other suitable solvent) and mixed with appropriate amounts and typesof pharmaceutical-grade excipients to form a matrix which is solid orsemi-solid at both room temperature and at the normal temperature of thehuman body. The matrix is completely or almost entirely resistant todigestion in the stomach and upper small intestine, and it graduallydisintegrates in the lower small intestine and/or colon.

In a suitable formulation, the matrix binds the 25-hydroxyvitamin Dcompound(s) and permits a slow, relatively steady, e.g. substantiallyconstant, release of 25-hydroxyvitamin D over a period of four to eighthours or more, by simple diffusion and/or gradual disintegration, intothe contents of the lumen of the lower small intestine and/or colon. Theformulation optionally further has an enteric coating that partiallydissolves in aqueous solutions having a pH of about 7.0 to 8.0, orsimply dissolves slowly enough that significant release of25-hydroxyvitamin D is delayed until after the formulation passesthrough the duodenum and jejunum.

As discussed above, the means for providing the controlled release of25-hydroxyvitamin D may be selected from any suitable controlled releasedelivery system, including any of the known controlled release deliverysystems of an active ingredient over a course of about four or morehours, including the wax matrix system, and the EUDRAGIT RS/RL system(Rohm Pharma, GmbH, Weiterstadt, Germany).

The wax matrix system provides a lipophilic matrix. The wax matrixsystem may utilize, for example, beeswax, white wax, cachalot wax orsimilar compositions. The active ingredient(s) are dispersed in the waxbinder which slowly disintegrates in intestinal fluids to graduallyrelease the active ingredient(s). The wax binder that is impregnatedwith 25-hydroxyvitamin D can be loaded into softgel capsules. A softgelcapsule may comprise one or more gel-forming agents, e.g., gelatin,starch, carrageenan, and/or other pharmaceutically acceptable polymers.In one embodiment, partially crosslinked soft gelatin capsules are used.As another option, vegetable-based capsules can be used. The wax matrixsystem disperses the active ingredient(s) in a wax binder which softensat body temperature and slowly disintegrates in intestinal fluids togradually release the active ingredient(s). The system suitably caninclude a mixture of waxes, with the optional addition of oils, toachieve a melting point which is higher than body temperature, but lowerthan the melting temperature of the selected formulations used to createthe shell of a soft or hard capsule, or vegetable capsule shell, orother formulation used to create a shell casing or other coating.

Specifically, in one suitable embodiment, the waxes selected for thematrix are melted and thoroughly mixed. The desired quantity of oils issubsequently added, followed by sufficient mixing for homogenization.The waxy mixture is then gradually cooled to a temperature just aboveits melting point. The desired amount of 25-hydroxyvitamin D, dissolvedin ethanol, is uniformly distributed into the molten matrix, and thematrix is loaded into capsules, for example vegetable-based orgelatin-based capsules. The filled capsules optionally are treated forappropriate periods of time with a solution containing an aldehyde, suchas acetaldehyde, to partially crosslink a polymer, e.g., gelatin, in thecapsule shell, when used. The capsule shell becomes increasinglycrosslinked, over a period of several weeks and, thereby, more resistantto dissolution in the contents of stomach and upper intestine. Whenproperly constructed, this gelatin shell will gradually dissolve afteroral administration and become sufficiently porous (without fullydisintegrating) by the time it reaches the ileum to allow the25-hydroxyvitamin D to diffuse slowly from the wax matrix into thecontents of the lower small intestine and/or colon.

Examples of other lipid matrices suitable for use with the methods ofthe invention include one or more of glycerides, fatty acids andalcohols, and fatty acid esters.

In one embodiment, a formulation may comprise an oily vehicle for the25-hydroxyvitamin D compound. Any pharmaceutically-acceptable oil can beused. Examples include animal (e.g., fish), vegetable (e.g., soybean),and mineral oils. The oil preferably will readily dissolve the25-hydroxyvitamin D compound used. Oily vehicles can includenon-digestible oils, such as mineral oils, particularly liquidparaffins, and squalene. The ratio between the wax matrix and the oilyvehicle can be optimized in order to achieve the desired rate of releaseof the 25-hydroxyvitamin D compound. Thus, if a heavier oil component isused, relatively less of the wax matrix can be used, and if a lighteroil component is used, then relatively more wax matrix can be used. Inone embodiment, the particular choice of oily vehicle provides acontrolled release so that absorption of 25-hydroxyvitamin D is delayeduntil the formulation reaches the ileum and/or colon.

Another suitable controlled-release oral drug delivery system is theEUDRAGIT RL/RS system in which the active 25-hydroxyvitamin D ingredientis formed into granules having a dimension of 25/30 mesh. The granulesare then uniformly coated with a thin polymeric lacquer, which iswater-insoluble but slowly water-permeable. The coated granules can bemixed with optional additives including one or more of antioxidants,stabilizers, binders, lubricants, processing aids and the like. Themixture may be compacted into a tablet which, prior to use, is hard anddry and can be further coated, or it may be poured into a capsule. Afterthe tablet or capsule is swallowed and comes into contact with theaqueous intestinal fluids, the thin lacquer begins to swell and slowlyallows permeation by intestinal fluids. As the intestinal fluid slowlypermeates the lacquer coating, the contained 25-hydroxyvitamin D isslowly released. By the time the tablet or capsule has passed throughthe small intestine, about four to eight hours or more later, the25-hydroxyvitamin D will have been slowly, but completely, released.Accordingly, the ingested tablet will release a stream of25-hydroxyvitamin D, as well as any other active ingredient.

The EUDRAGIT system is comprised of high permeability lacquers (RL) andlow permeability lacquers (RS). RS is a water-insoluble film formerbased on neutral swellable methacrylic acids esters with a smallproportion of trimethylammonioethyl methacrylate chlorides; the molarratio of the quaternary ammonium groups to the neutral ester group isabout 1:40. RL is also a water insoluble swellable film former based onneutral methacrylic acid esters with a small portion oftrimethylammonioethyl methacrylate chloride, the molar ratio ofquaternary ammonium groups to neutral ester groups is about 1:20. Thepermeability of the coating and thus the time course of drug release canbe titrated by varying the proportion of RS to RL coating material. Forfurther details of the Eudragit RL/RS system, reference is made totechnical publications available from Rohm Tech, Inc. 195 Canal Street,Maiden, Mass., 02146 and K. Lehmann, D. Dreher “Coating of tablets andsmall particles with acrylic resins by fluid bed technology,” Int. J.Pharm. Tech. & Prod. Mfr. 2(r), 31-43 (1981), incorporated herein byreference.

Other examples of insoluble polymers include polyvinyl esters, polyvinylacetals, polyacrylic acid esters, butadiene styrene copolymers and thelike.

In one embodiment, once the coated granules are either formed into atablet or put into a capsule, the tablet or capsule is coated with anenteric-coating material which dissolves at a pH of 7.0 to 8.0. One suchpH-dependent enteric-coating material is EUDRAGIT L/S which dissolves inintestinal fluid, but not in the gastric juices. Other enteric-coatingmaterials may be used such as cellulose acetate phthalate (CAP), whichis resistant to dissolution by gastric juices, but readily disintegratesdue to the hydrolytic effect of the intestinal esterases.

In one embodiment, the particular choice of enteric-coating material andcontrolled release coating material provides a controlled andsubstantially constant release over a period of 4 to 8 hours or more sothat substantial release is delayed until the formulation reaches theileum. Optionally, a controlled release composition in accordance withthe present disclosure, when administered once a day, can suitablyprovide substantially constant intralumenal, intracellular and blood25-hydroxyvitamin D levels compared to an equal dose of an immediaterelease composition of 25-hydroxyvitamin D administered once a day.

The dosage forms may also contain adjuvants, such as preserving orstabilizing adjuvants. For example, a preferred formulation includes25-hydroxyvitamin D (e.g., about 30 mcg, about 60 mcg, or about 90 mcg25-hydroxyvitamin D₃), about 2 wt % anhydrous ethanol, about 10 wt %lauroyl polyoxylglycerides, about 20 wt % hard paraffin, about 23 wt %glycerol monostearate, about 35 wt % liquid paraffin or mineral oil,about 10 wt % hydroxypropyl methylcellulose, and optionally a smallamount of preservative (e.g., butylated hydroxytoluene). Formulationsaccording to the invention may also contain other therapeuticallyvaluable substances or may contain more than one of the compoundsspecified herein and in the claims in admixture.

As an alternative to oral 25-hydroxyvitamin D, intravenousadministration of 25-hydroxyvitamin D is also contemplated. In oneembodiment, the 25-hydroxyvitamin D is administered as a sterileintravenous bolus, optionally a bolus injection of a composition thatresults in a sustained release profile. In another embodiment, the25-hydroxyvitamin D is administered via gradual injection/infusion,e.g., over a period of 1 to 5 hours, to effect controlled orsubstantially constant release of the 25-hydroxyvitamin D directly toDBP in the blood of the patient. For example, the composition may beinjected or infused over a course of at least about 1 hour, at leastabout 2 hours, at least about 3 hours, at least about 4 hours, at leastabout 5 hours, or at least about 6 hours. In one embodiment, thecomposition intended for intravenous administration in accordance withthe present invention is designed to contain a concentration of the25-hydroxyvitamin D compound(s) of 1 to 100 mcg per unit dose. Sterile,isotonic formulations of 25-hydroxyvitamin D may be prepared bydissolving 25-hydroxyvitamin D in absolute ethanol, propylene glycol oranother suitable solvent, and combining the resulting solution with oneor more surfactants, salts and preservatives in appropriate volumes ofwater for injection. Such formulations can be administered slowly fromsyringes, for example, via heparin locks, or by addition to largervolumes of sterile solutions (e.g., saline solution) being steadilyinfused over time. In one embodiment, the composition can be co-injectedor co-infused with an anticancer agent.

In another aspect, administration of an effective amount of acomposition of the present disclosure can be effective to safely achievesupraphysiologic levels of 25-hydroxyvitamin D and/or1,25-dihydroxyvitamin D i.e., without causing hypercalcemia and/orhyperphosphatemia.

Advantageously, adjunctive therapy comprising 25-hydroxyvitamin D and anagent that increases the risk of hypocalcemia and/or an anticanceragent, optionally together with other therapeutic agents, can be orallyor intravenously administered in accordance with the above describedembodiments in dosage amounts of from 1 to 1000 mcg 25-hydroxyvitamin Dper day, with the preferred dosage amounts of from 5 mcg to 50 mcg, from30mcg to 90 mcg, from 100 mcg to 500 mcg, from 600 mcg to 900 mcg, from200 mcg to 700 mcg, or from 500 mcg to 1000 mcg 25-hydroxyvitamin D perday. If the 25-hydroxyvitamin D and an agent that increases the risk ofhypocalcemia and/or an anticancer agent are co-administered incombination with other therapeutic agents, the proportions of each ofthe compounds in the combination being administered will be dependent onthe particular disease state being addressed. For example, one maychoose to orally administer 25-hydroxyvitamin D with one or more calciumsalts (intended as a calcium supplement or dietary phosphate binder),calcimimetics, nicotinic acid, iron, phosphate binders, cholecalciferol,ergocalciferol, active Vitamin D sterols, or glycemic and hypertensioncontrol agents. In addition, one may choose to intravenously administer25-hydroxyvitamin D with cholecalciferol, ergocalciferol, active VitaminD sterols, or glycemic and hypertension control agents. In practice,higher doses of the compounds of the present disclosure are used wheretherapeutic treatment of a disease state is the desired end, while thelower doses are generally used for prophylactic purposes, it beingunderstood that the specific dosage administered in any given case willbe adjusted in accordance with the specific compounds beingadministered, the disease to be treated, the condition of the subjectand the other relevant medical facts that may modify the activity of thedrug or the response of the subject, as is well known by those skilledin the art.

The present invention is further explained by the following exampleswhich should not be construed by way of limiting the scope of thepresent invention.

EXAMPLE 1 One Embodiment of a Modified Release Formulation for OralAdministration

Purified yellow beeswax and fractionated coconut oil are combined in aratio of 1:1 and heated with continuous mixing to 75 degrees Celsiusuntil a uniform mixture is obtained. The wax mixture is continuouslyhomogenized while cooled to approximately 45 degrees Celsius. The activecompounds, 25-hydroxyvitamin D₂ and 25-hydroxyvitamin D₃, in a ratio of1:1, are dissolved in absolute ethanol and the ethanolic solution isadded, with continuous homogenization, to the molten wax mixture. Theamount of ethanol added is in the range of 1 to 2 v/v%. Mixing iscontinued until the mixture is uniform. The uniform mixture is loadedinto soft gelatin capsules. The capsules are immediately rinsed toremove any processing lubricant(s) and briefly immersed in an aqueoussolution of acetaldehyde in order to crosslink the gelatin shell. Theconcentration of the acetaldehyde solution and the immersion time isselected to achieve crosslinking to the desired degree, as determined bynear-infrared spectrophotometry. The finished capsules are washed, driedand packaged.

EXAMPLE 2 One Embodiment of a Formulation for Intravenous Administration

TWEEN Polysorbate 20 is warmed to approximately 50 to 60 degreesFahrenheit, and 25-hydroxyvitamin D₃, dissolved in a minimal volume ofabsolute ethanol, is added with continuous stirring. The resultinguniform solution of 25-hydroxyvitamin D₃, absolute ethanol and TWEENPolysorbate 20 is transferred to a suitable volume of water forinjection, which has been thoroughly sparged with nitrogen to remove alldissolved oxygen. Sodium chloride, sodium ascorbate, sodium phosphate(dibasic and monobasic), and disodium edetate are added, followed bysufficient stirring under a protective nitrogen atmosphere, to producean isotonic homogeneous mixture containing, per 2 mL unit volume: 20 mcgof 25-hydroxyvitamin D₃; less than 0.01% absolute ethanol; 0.40% (w/v)TWEEN Polysorbate 20; 0.15% (w/v) sodium chloride; 1.00% (w/v) sodiumascorbate; 0.75% (w/v) sodium phosphate dibasic anhydrous; 0.18% (w/v)sodium phosphate monobasic monohydrate; and, 0.11% (w/v) disodiumedetate. The mixture is sterilized by filtration and filled, withsuitable protection from oxygen contamination, into amber glass ampuleshaving an oxygen headspace of less than 1%.

EXAMPLE 3 Pharmacokinetics Testing in Dogs

Twenty male beagle dogs are divided randomly into two comparable groupsand receive no supplemental Vitamin D for the next 30 days. At the endof this time, each dog in Group #1 receives a single softgel capsulecontaining 25 mcg of 25-hydroxyvitamin D₂ prepared in a controlledrelease formulation similar to the one disclosed in Example 1. Each dogin the other group (Group #2) receives a single immediate-releasesoftgel capsule containing 25 mcg of 25-hydroxyvitamin D₂ dissolved inmedium chain triglyceride oil. All dogs have received no food for atleast 8 hours prior to dosing. Blood is drawn from each dog at 0, 0.5,1, 1.5, 2, 3, 4, 6, 9, 15, 24, 36, and 72 hours after doseadministration. The collected blood is analyzed for the contained levelsof 25-hydroxyvitamin D, and the data are analyzed by treatment group.Dogs in Group #1 show a slower rise and a lower maximum (C_(max)) inmean blood levels of 25-hydroxyvitamin D than dogs in Group #2. However,dogs in Group #1 show a more prolonged elevation of mean blood levels of25-hydroxyvitamin D₂ relative to dogs in Group #2, despite the fact thatthe C_(max) recorded in Group #1 is lower. The mean area under the curve(AUC), corrected for predose background levels (recorded at t=0), issubstantially greater for Group #1 for 25-hydroxyvitamin D. Theseprocedures demonstrate that administration of 25-hydroxyvitamin D₂ inthe formulation described in this invention to dogs results in bloodlevels of 25-hydroxyvitamin D which rise much more gradually and remainmore stable than after dosing with the same amount of 25-hydroxyvitaminD₂ formulated for immediate release (in medium chain triglyceride oil).The greater AUC calculated for blood levels of 25-hydroxyvitamin D inGroup #1 demonstrates that the bioavailability of 25-hydroxyvitamin D₂formulated as described herein is markedly improved.

EXAMPLE 4 Pharmacokinetics Testing in Healthy Normal Volunteers

Sixteen healthy non-obese adults, aged 18 to 24 years, participate in an11-week pharmacokinetic study in which they receive successively, and ina double-blinded fashion, two formulations of 25-hydroxyvitamin D₂. Oneof the formulations (Formulation #1) is a softgel capsule containing 100mcg of 25-hydroxyvitamin D₂ prepared in a controlled release formulationsimilar to the one disclosed in Example 1. The other formulation(Formulation #2) is an immediate-release softgel capsule of identicalappearance containing 100 mcg of 25-hydroxyvitamin D₂ dissolved inmedium chain triglyceride oil. For 60 days prior to study start andcontinuing through study termination, the subjects abstain from takingother Vitamin D supplements. On Days 1, 3 and 5 of the study, allsubjects provide fasting morning blood samples to establishpre-treatment baseline values. On the morning of Day 8, the subjectsprovide an additional fasting blood sample (t=0), and are randomlyassigned to one of two treatment groups. Both groups are dosed with asingle test capsule prior to eating breakfast: One group receives acapsule of Formulation #1 and the other group receives a capsule ofFormulation #2. Blood is drawn from each subject at 0.5, 1, 1.5, 2, 3,4, 6, 8, 10, 12, 15, 24, 36, 48, 72 and 108 hours after doseadministration. On the morning of Day 70, the subjects provideadditional fasting morning blood samples (t=0) and are dosed with asingle capsule of the other test formulation prior to eating breakfast.Blood is again drawn from each subject at 0.5, 1, 1.5, 2, 3, 4, 6, 8,10, 12, 15, 24, 36, 48, 72 and 108 hours after dose administration. Allcollected blood is analyzed for the contained levels of25-hydroxyvitamin D, and the data are analyzed by treatment formulationafter correction for baseline content. Formulation #1 is found toproduce a slower rise and a lower C_(max) in mean blood levels of25-hydroxyvitamin D than Formulation #2. However, Formulation #1 alsoproduces a more prolonged elevation of mean blood levels of25-hydroxyvitamin D₂ relative to Formulation #2, despite the fact thatthe recorded C_(max) is lower. The mean AUC for 25-hydroxyvitamin D₂ issubstantially greater after administration of Formulation #1. Theseprocedures demonstrate that administration of 25-hydroxyvitamin D₂ inthe formulation described in this invention to healthy human adultsresults in blood levels of 25-hydroxyvitamin D₂ which rise much moregradually and remain more stable than after dosing with the same amountof 25-hydroxyvitamin D₂ formulated for immediate release (in mediumchain triglyceride oil). The greater AUC calculated for blood levels of25-hydroxyvitamin D₂ after dosing with Formulation #1 demonstrates thatthe bioavailability of 25-hydroxyvitamin D₂ formulated as describedherein is better.

EXAMPLE 5 Efficacy Study in Healthy Adult Male Volunteers With Vitamin DInsufficiency

The effectiveness of three different formulations of Vitamin D inrestoring serum total 25-hydroxyvitamin D to optimal levels (>30 ng/mL)is examined in a 23-day study of healthy non-obese men diagnosed withVitamin D insufficiency. One of the formulations (Formulation #1) is asustained release softgel capsule containing 30 mcg of 25-hydroxyvitaminD₃ prepared as illustrated in this disclosure. The second formulation(Formulation #2) is an immediate-release softgel capsule of identicalappearance containing 50,000 IU of ergocalciferol dissolved in mediumchain triglyceride oil. The third formulation (Formulation #3) is animmediate-release softgel capsule, also of identical appearance,containing 50,000 IU of cholecalciferol dissolved in medium chaintriglyceride oil. A total of 100 healthy Caucasian and African-Americanmen participate in this study, all of whom are aged 30 to 45 years andhave serum 25-hydoxyvitamin D levels between 15 and 29 ng/mL(inclusive). All subjects abstain from taking other Vitamin Dsupplements for 60 days before study start and continuing through studytermination, and from significant sun exposure. On Day 1 and 2 of thestudy, all subjects provide fasting morning blood samples to establishpre-treatment baseline values of serum total 25-hydroxyvitamin D. On themorning of Day 3, the subjects provide an additional fasting bloodsample (t=0), are randomly assigned to one of four treatment groups, andare dosed with a single test capsule prior to eating breakfast: Thesubjects in Group #1 each receive a single capsule of Formulation #1,and the subjects in Groups #2 and #3 each receive a single capsule ofFormulation #2 or Formulation #3, respectively. Subjects in Group #4receive a matching placebo capsule. Subjects in Group #1 each receive anadditional capsule of Formulation #1 on the mornings of Days 4 through22 before breakfast, but subjects in Groups #2, #3 and #4 receive noadditional capsules. A fasting morning blood sample is drawn from eachsubject, irrespective of treatment group, on Days 4, 5, 6, 10, 17 and 23(or 1, 2, 3, 7, 14 and 20 days after the start of dosing). All collectedblood is analyzed for the contained levels of 25-hydroxyvitamin D, andthe data are analyzed by treatment group after correction for baselinevalues. Subjects in all four treatment groups exhibit mean baselineserum 25-hydoxyvitamin D levels of approximately 16 to 18 ng/mL, basedon analysis of fasting blood samples drawn on Days 1 through 3. Subjectsin Group #4 (control group) show no significant changes in mean serumtotal 25-hydroxyvitamin D over the course of the study. Subjects inGroup #1 show a steadily increasing mean serum total 25-hydroxyvitamin Dreaching at least 30 ng/mL by Day 23. In marked contrast, subjects inGroup #2 exhibit marked increases in mean serum 25-hydroxyvitamin D forthe first few days post-dosing, reaching a maximum of just above 25ng/mL, and then rapidly declining thereafter. By study end, serum total25-hydroxyvitamin D is significantly lower than baseline in Group #2.Subjects in Group #3 exhibit continuing increases in mean serum total25-hydroxyvitamin D through the first 2 weeks after dosing with gradual,but progressive, decreases occurring thereafter. By study end, meanserum total 25-hydroxyvitamin D is below 30 ng/mL. The data from thisstudy demonstrate that administration of 600 mcg of 25-hydroxyvitaminD₃, formulated as described herein and administered at a dose of 30 mcgper day for 20 days, is substantially more effective in restoring lowserum levels of 25-hydroxyvitamin D to optimal levels thanimmediate-release formulations of 50,000 IU of either ergocalciferol orcholecalciferol administered in single doses, as currently recommendedby the NKF and other leading experts on oral Vitamin D replacementtherapy.

EXAMPLE 6 Efficacy Study in Osteoporosis Patients Treated with anAntiresorptive Agent

The effectiveness of oral modified release 25-hydroxyvitamin D₃ inrestoring serum total 25-hydroxyvitamin D to optimal levels (>30 ng/mL),and thereby optimizing the effectiveness of an antiresorptive agent atincreasing bone mineral density, is examined in a 24-month study ofadult male and female patients with osteoporosis. In a randomized,double-blind controlled study, patients are treated with denosumab (60mg at the start of treatment and again every six months). Alldenosumab-treated patients are randomized to receive daily oraltreatment with one softgel capsule containing either 30 mcg of25-hydroxyvitamin D₃ in a modified release formulation or 400 IU ofVitamin D₃ (cholecalciferol) in an immediate release formulation. Atotal of 500 subjects participate in this study, 250 male and 250female, all of whom are aged 60 to 85 years (inclusive), have bonemineral density T-scores between −2.0 and −4.0, and have serum total25-hydroxyvitamin D levels less than 30 ng/mL at the time of enrollment.All subjects receive calcium supplements (500 mg/day) and abstain fromtaking other Vitamin D supplements for 60 days before study start andcontinuing through study termination, and from significant sun exposure.All subjects begin daily dosing with softgel capsules at the start ofdenosumab treatment. Serum total 25-hydroxyvitamin D, PTH, calcium,phosphorus, N- and C-telopeptides, and P1NP, and urinary calcium,phosphorus and creatinine, are measured monthly. Bone mineral density atfour sites (total hip, femoral neck, ⅓ radius and lumbar spine) isdetermined at quarterly intervals.

After 3 months, the daily softgel capsule dosage is maintained unchangedin patients whose serum total 25-hydroxyvitamin D is between 50 and 90ng/mL, and increased by one capsule in patients whose serum total25-hydroxyvitamin D is below 50 ng/mL. The dosage is immediately loweredby one capsule per day in patients whose serum total 25-hydroxyvitamin Drises above 100 ng/mL or whose serum calcium is confirmed above 10.3mg/dL. After 6 to 9 months, all subjects exhibit serum total25-hydroxyvitamin D levels that remain essentially stable withcontinuing dosing and rise to approximately 50 to 100 ng/mL with25-hydroxyvitamin D₃ treatment or to approximately 25 to 35 ng/mL withVitamin D₃ treatment. In patients treated with 25-hydroxyvitamin D₃, theincidence of hypocalcemia and severity of secondary hyperparathyroidismis markedly reduced once stable dosing has been achieved. However, inpatients treated with Vitamin D₃, hypocalcemia and secondaryhyperparathyroidism occur more frequently. After 24 months of treatment,the patients treated with denosumab and 25-hydroxyvitamin D₃ are foundto have higher and more consistent serum levels of 25-hydroxyvitamin D₃and lower serum PTH levels than patients treated with denosumab andVitamin D₃. Patients treated with denosumab and 25-hydroxyvitamin D₃ arealso found to have larger increases in bone mineral density thanpatients treated with denosumab and Vitamin D₃. Data from this studydemonstrate that the modified release formulation of 25-hydroxyvitaminD₃ is effective at increasing serum total 25-hydroxyvitamin D withoutcausing unacceptable side effects related to calcium and PTH metabolismand at augmenting the increases in bone mineral density produced bydenosumab.

EXAMPLE 7 Efficacy Study in Prostate Cancer Patients

The effectiveness of oral modified release 25-hydroxyvitamin D₃ inrestoring serum total 25-hydroxyvitamin D to optimal levels (greaterthan 30 ng/mL), thereby mitigating iatrogenic hypocalcemia and secondaryhyperparathyroidism, and optimizing the effectiveness of anantiresorptive agent at mitigating skeletal-related events in prostatecancer patients, is examined in a 24-month study of adult male patientswith bone-metastasized castration-resistant prostate cancer. In arandomized, double-blind controlled study, patients are treated withdenosumab (120 mg every four weeks). All denosumab-treated patients arerandomized to receive daily oral treatment with one softgel capsulecontaining either 30 mcg of 25-hydroxyvitamin D₃ in a modified releaseformulation or 400 IU of Vitamin D₃ in an immediate release formulation.A total of 500 subjects participate in this study, all of whom are aged18 years or older with histologically confirmed prostate cancer. Priorto study admission, patients had to have received treatment for prostatecancer (e.g., bilateral orchiectomy or androgen-deprivation therapy forat least 6 months), have total serum testosterone lower than 50 ng/dL,and have three consecutive increasing PSA tests separated by at least 2weeks with the last two PSA measurements greater than or equal to 1.0mcg/L. All patients have serum total 25-hydroxyvitamin D levels lessthan 30 ng/mL at the time of enrollment. All patients receive aradioisotope bone scan during screening with subsequent imaging by CT,MRI, or plain radiograph if needed to confirm bone metastases. Allsubjects receive calcium supplements (500 mg/day) and abstain fromtaking other Vitamin D supplements for 60 days before study start andcontinuing through study termination, and from significant sun exposure.

All subjects begin daily dosing with softgel capsules at the start ofdenosumab treatment. Serum total 25-hydroxyvitamin D, PTH, calcium,phosphorus, N- and C-telopeptides, and P1NP, and urinary calcium,phosphorus and creatinine, are measured monthly. Radiographic bone scansare conducted every 6 months to detect skeletal metastases, with asecond imaging modality (CT, MRI, or plain radiograph) used to confirmdiagnosis of any metastases detected. Bone mineral density at four sites(total hip, femoral neck, ⅓ radius and lumbar spine) is determined atthe start of the study and thereafter at yearly intervals. After 3months, the daily dosage of 25-hydroxyvitamin D₃ capsules is maintainedunchanged in patients whose serum total 25-hydroxyvitamin D is between50 and 90 ng/mL, and increased by one 30 mcg capsule in patients whoseserum total 25-hydroxyvitamin D is below 50 ng/mL. The dosage isimmediately lowered by one 30 mcg capsule per day in patients whoseserum total 25-hydroxyvitamin D rises above 100 ng/mL or whose serumcalcium is confirmed above 10.3 mg/dL.

After 6 months to 9 months, all subjects exhibit serum total25-hydroxyvitamin D levels essentially stable in a range of 50 ng/mL to90 ng/mL with 25-hydroxyvitamin D₃ treatment or between approximately 25ng/mL to 35 ng/mL with Vitamin D₃ treatment. In patients treated with25-hydroxyvitamin D₃, the incidence of hypocalcemia and severity of SHPTand hypercalcemia is markedly reduced once stable dosing has beenachieved. In contrast, patients treated with Vitamin D₃ exhibithypercalcemia and SHPT more frequently. After 24 months of treatment,the patients treated with denosumab and 25-hydroxyvitamin D₃ are foundto have higher and more consistent serum levels of 25-hydroxyvitamin D₃and lower serum PTH levels than patients treated with denosumab andvitamin D₃. Patients treated with denosumab and 25-hydroxyvitamin D₃ arefound to have a significantly lower incidence of hypocalcemia, reducedplasma PTH levels and larger increases in bone mineral density and tohave a significantly delayed time to first post-treatment SRE, comparedto patients treated with denosumab and Vitamin D₃. Data from this studydemonstrate that the modified release formulation of 25-hydroxyvitaminD₃ is effective at increasing serum 25-hydroxyvitamin D without causingunacceptable side effects related to calcium and PTH metabolism, and atmitigating hypocalcemia and augmenting the increases in bone mineraldensity and delayed time to first bone metastasis produced by denosumab.

EXAMPLE 8 Efficacy Study in Breast Cancer Patients

The effectiveness of oral modified-release 25-hydroxyvitamin D₃ inrestoring serum total 25-hydroxyvitamin D to optimal levels (greaterthan 30 ng/mL), thereby mitigating hypocalcemia and SHPT and optimizingthe effectiveness of denosumab at mitigating SRE in breast cancerpatients, is examined in a 24-month study of adult female patients withbreast cancer. In a randomized, double-blind controlled study, patientsare treated with denosumab (120 mg every four weeks). Alldenosumab-treated patients are randomized to receive daily oraltreatment with one softgel capsule containing either 30 mcg of25-hydroxyvitamin D₃ in a modified release formulation or 400 IU ofcholecalciferol in an immediate release formulation. All subjectsparticipating in this study are aged 18 years or older withhistologically or cytologically confirmed breast adenocarcinoma andcurrent or prior radiographic (x-ray, CT or MRI) evidence of at leastone bone metastasis. All subjects receive calcium supplements (500mg/day) and abstain from taking other Vitamin D supplements for 60 daysbefore study start and continuing through study termination, and fromsignificant sun exposure. All subjects begin daily dosing with softgelcapsules at the start of denosumab treatment. Serum total25-hydroxyvitamin D, PTH, calcium, phosphorus, N- and C-telopeptides,and P1NP, and urinary calcium, phosphorus and creatinine, are measuredmonthly. Radiographic bone scans are conducted every 6 months to monitorskeletal metastases, with a second imaging modality (CT, MRI, or plainradiograph) used to confirm any metastases detected. Bone mineraldensity at four sites (total hip, femoral neck, ⅓ radius and lumbarspine) is determined at the start of the study and thereafter at yearlyintervals. After 3 months, the daily softgel capsule dosage ismaintained unchanged in patients whose serum total 25-hydroxyvitamin Dis between 50 and 90 ng/mL and increased by one mcg capsule in patientswhose serum total 25-hydroxyvitamin D is below 50 ng/mL. The dosage isimmediately lowered by one capsule per day in patients whose serum total25-hydroxyvitamin D rises above 100 ng/mL or whose serum calcium isconfirmed above 10.3 mg/dL. After 6 to 9 months, the subjects' serumtotal 25-hydroxyvitamin D levels remain essentially stable withcontinued dosing, and rise to a level between about 50 ng/mL and about90 ng/mL with 25-hydroxyvitamin D₃ treatment or to approximately 25 to35 ng/mL with cholecalciferol treatment.

In patients treated with 25-hydroxyvitamin D₃, the incidence ofhypocalcemia and severity of secondary hyperparathyroidism are markedlyreduced once stable dosing has been achieved. However, in patientstreated with vitamin D₃, hypocalcemia and secondary hyperparathyroidismoccur more frequently. After 24 months of treatment, the patientstreated with denosumab and 25-hydroxyvitamin D₃ are found to have higherand more consistent serum levels of 25-hydroxyvitamin D₃ and lower serumPTH levels than are patients treated with denosumab and vitamin D₃.Patients treated with denosumab and 25-hydroxyvitamin D₃ are found tohave a significantly lower incidence of hypocalcemia and largerincreases in bone mineral density and to have a significantly delayedtime to additional bone metastasis, compared to patients treated withdenosumab and Vitamin D₃. Data from this study demonstrate that themodified release formulation of 25-hydroxyvitamin D₃ is effective atincreasing serum total 25-hydroxyvitamin D without causing unacceptableside effects related to calcium and PTH metabolism, and at mitigatinghypocalcemia and augmenting the increases in bone mineral density anddelayed time to bone metastasis produced by denosumab.

EXAMPLE 9 Safety Study in Patients with Metastatic Bone DiseaseReceiving Treatment with an Antiresorptive Agent

The safety and tolerability of oral modified release 25-hydroxyvitaminD₃ is examined in an open label, repeat-dose study of adult patientsdiagnosed with metastases in bone originating from breast or prostatecancer who are receiving ongoing treatment with denosumab or zoledronicacid for at least 3 months. At the start of the study, all patients haveplasma PTH greater than 70 pg/mL as evidence of SHPT, serum calcium lessthan 9.8 mg/dL, spot urine Ca:Cr ratio≦0.25 (≦250 mg/g creatinine) andan estimated glomerular filtration rate greater than 15 mL/min/1.73 m².Twenty-four (24) patients diagnosed with bone metastases subsequent tobreast or pancreatic carcinoma are treated for up to 52 weeks with oneor more capsules containing 30 mcg of 25-hydroxyvitamin D₃ in a modifiedrelease formulation. Denosumab or zoledronic acid are administeredaccording to the typical standard of care for each patient's condition.Patients whose typical standard of care requires calcium and/or vitaminD supplementation receive less than 1000 mg/day of elemental calciumand/or 2000 IU/day or less of vitamin D (ergocalciferol and/orcholecalciferol). Patients do not receive any other vitamin D analogs(e.g., calcitriol, paricalcitol, doxercalciferol, etc.).

The 52-week study consists of a 40 week dose escalation phase followedby a 12-week maintenance phase. At the end of the maintenance phase,there is a two-week follow up phase. At the start of the study, allpatients receive an initial daily dose of 30 mcg 25-hydroxyvitamin D₃,which is increased at four-week intervals over the course of the doseescalation phase up to a maximum daily dose of 300 mcg. The daily doseachieved by the end of the dose escalation study is the daily doseadministered during the maintenance phase. Patients exhibiting a serumcalcium level ≦10.3 mg/dL of the course of the study thus receive adaily dose of: 30 mcg 25-hydroxyvitamin D₃ at the start of the study; 60mcg 25-hydroxyvitamin D₃ after 4 weeks; 90 mcg 25-hydroxyvitamin D₃ at 8weeks; 120 mcg 25-hydroxyvitamin D₃ at 12 weeks; 150 mcg25-hydroxyvitamin D₃ at 16 weeks; 180 mcg 25-hydroxyvitamin D₃ at 20weeks; 210 mcg 25-hydroxyvitamin D₃ at 24 weeks; 240 mcg25-hydroxyvitamin D₃ at 28 weeks; 270 mcg 25-hydroxyvitamin D₃ at 32weeks; and 300 mcg 25-hydroxyvitamin D₃ at 36 weeks and through themaintenance phase. Patients exhibiting a serum calcium level exceeding10.3 mg/dL for two consecutive visits will suspend dosing until serumcalcium returns to ≦10.0 mg/dL, and then resume treatment at a reduceddaily dose and enter a 12-week maintenance phase, followed by a 2-weekfollow-up period.

Blood samples are collected at 2-week intervals for monitoring serumlevels of calcium and phosphorus. Samples are collected at 4-weekintervals for monitoring plasma levels of PTH and PTHrP and serum total25-hydroxyvitamin D, 24,25-dihydroxyvitamin D₃, calcitriol, and free andtotal calcifediol. Serum vitamin D metabolites and markers of bonemetabolism, immune function, and tumor burden are measured at thebeginning of the dose escalation phase and at the beginning and end ofthe maintenance phase. Urine samples are collected at 4-week intervalsfor monitoring the Ca/Cr ratio and urine chemistry. The genotype ofvitamin D binding protein is determined for each subject at thebeginning of the dose escalation phase.

Serum calcium gradually rises in the dose escalation phase while plasmaPTH decreases. When plasma PTH is overly suppressed, serum calcium risesmore quickly with continued dose escalation, increasing the risk ofhypercalcemia. Patients exhibit significant increases in serum total25-hydroxyvitamin D, 1,25-dihydroxyvitamin D, and 24,25-dihydroxyvitaminD, and decreases in plasma PTH. Patients receiving the starting doselevel of 30 mcg of 25-hydroxyvitamin D₃ exhibit mean serum25-hydroxyvitamin D levels of about 50 ng/mL. Patients receiving thedose level of 90 mcg of 25-hydroxyvitamin D₃ exhibit mean serum25-hydroxyvitamin D levels of about 100 mg/mL. Patients receiving thehighest dose level of 300 mcg of 25-hydroxyvitamin D₃ exhibit mean serum25-hydroxyvitamin D levels of about 200 to about 300 ng/mL, for example,about 230 ng/mL. Data from this study demonstrate that a modifiedrelease formulation of 25-hydroxyvitamin D₃ is effective at increasingserum total 25-hydroxyvitamin D without causing unacceptable sideeffects related to calcium and PTH metabolism.

EXAMPLE 10 Efficacy Study in Patients with Metastatic Bone DiseaseReceiving Treatment With an Antiresorptive Agent

The effectiveness of oral modified-release 25-hydroxyvitamin D₃ inraising serum 25-hydroxyvitamin D and 1,25-dihydroxyvitamin D anddelaying cancer progression is examined in a 6-month randomized,double-blind placebo-controlled study of adult patients diagnosed withmetastases in bone originating from breast or prostate cancer who arereceiving ongoing treatment with denosumab or zoledronic acid for atleast 3 months. Patients are treated with one or more capsulescontaining 30 mcg of 25-hydroxyvitamin D₃ in a modified releaseformulation or placebo. Denosumab or zoledronic acid are administeredaccording to the typical standard of care for each patient's condition.Patients whose typical standard of care requires calcium and/or vitaminD supplementation receive less than 1000 mg/day of elemental calciumand/or 2000 IU/day or less of vitamin D (ergocalciferol and/orcholecalciferol). Samples are collected at monthly intervals formonitoring serum and urine levels of calcium, plasma levels of PTH andserum total 25-hydroxyvitamin D. Serum markers of tumor burden and bonemetabolism, as well as cancer progression are assessed at 3-monthintervals.

Patients treated with 25-hydroxyvitamin D₃ are found to have a greaterincrease in serum calcium and decrease in plasma PTH, leading to reducedrisk of hypocalcemia compared to patients receiving the placebo.Patients treated with denosumab or zoledronic acid and 25-hydroxyvitaminD exhibit an increased delay in time to additional bone metastasis,compared to patients receiving denosumab or zoledronic acid incombination with a placebo. Data from this study demonstrate that themodified release formulation of 25-hydroxyvitamin D₃ is effective atincreasing serum total 25-hydroxyvitamin D 1,25-dihydroxyvitamin D anddelaying cancer progression, without causing unacceptable side effectsrelated to calcium and PTH metabolism.

EXAMPLE 11 Efficacy Study in Patients with Metastatic Bone DiseaseReceiving Treatment with an Antiresorptive Agent for Prevention of SREs

The effectiveness of oral modified release 25-hydroxyvitamin D₃ indelaying the time to the first post-treatment SRE is examined in24-month randomized, double-blind placebo-controlled studies of adultmales with castration-resistant prostate cancer metastatic to bone oradult females with estrogen-independent breast cancer metastatic tobone, who are receiving ongoing treatment with denosumab or zoledronicacid for at least 3 months. Patients are treated with one or morecapsules containing 30 mcg of 25-hydroxyvitamin D₃ in a modified releaseformulation or placebo. Denosumab or zoledronic acid are administeredaccording to the typical standard of care for each patient's condition.Patients are monitored for SREs, including by appropriate non-invasiveimaging techniques, and serum markers of tumor burden and bonemetabolism at 3-month intervals, and at monthly intervals for serum andurine calcium levels and plasma PTH. Cancer progression is monitored atquarterly intervals.

Patients treated with 25-hydroxyvitamin D₃ are found to have a greaterincrease in serum calcium and decrease in plasma PTH, leading to reducedrisk of hypocalcemia compared to patients receiving the placebo.Patients treated with denosumab or zoledronic acid and 25-hydroxyvitaminD exhibit an increased delay in time to additional bone metastasis orSRE, compared to patients receiving denosumab or zoledronic acid incombination with a placebo. Data from this study demonstrate that25-hydroxyvitamin D₃ is effective at significantly increasing theobserved time to a post-treatment SRE and inhibiting tumor progressioncompared to placebo.

EXAMPLE 12 Efficacy Study of Combination Therapy Comprising25-Hydroxyvitamin D and Cinacalcet in Patients with CKD

The effectiveness of a composition comprising modified release25-hydroxyvitamin D₃ and immediate release cinacalcet in preventing andtreating hypocalcemia and treating secondary hyperparathyroidism isexamined in a randomized, double-blind study of adult patients havingCKD. Patients having CKD on dialysis (i.e., having CKD Stage 5), and noton dialysis (i.e., having CKD Stage 1, 2, 3, or 4) are treated dailywith combination therapy comprising at least one capsule comprising both30 mcg to 100 mcg 25-hydroxyvitamin D and 1 mg to 100 mg cinacalcet HCland are compared to patients receiving placebo or 25-hydroxyvitamin D orcinacalcet alone. All patients have serum total 25-hydroxyvitamin Dlevels less than 30 ng/mL at the time of enrollment. Serum total25-hydroxyvitamin D, parathyroid hormone, calcium, and phosphorus, aremeasured before treatment and then monthly.

After one to three months, all patients receiving the combinationtherapy exhibit serum total 25-hydroxyvitamin D levels essentiallystable in a range of 50 ng/mL to 90 ng/mL and the incidence ofhypocalcemia and severity of secondary hyperparathyroidism is markedlyreduced. Patients having CKD on dialysis exhibit improvements in serum25-hydroxyvitamin D, calcium, and parathyroid hormone levels followingtreatment with the combination therapy, despite having very severelyreduced or no kidney function. Patients having CKD not on dialysisreceiving the combination therapy have an incidence of hypocalcemiacomparable to patients having CKD not on dialysis, in contrast toprevious reports indicating that cinacalcet-treated patients with CKDnot on dialysis had an increased risk for hypocalcemia compared tocinacalcet-treat patient with CKD on dialysis.

The foregoing description has outlined, in general, the featured aspectsof the invention. In reference to such, there is to be a clearunderstanding that the present invention is not limited to the method ordetail of manufacture, chemical composition, or application of usedescribed herein. Any other variation of manufacture, chemicalcomposition, use, or application should be considered apparent as analternative embodiment of the present invention. Other advantages and afuller appreciation of the specific adaptations, compositionalvariations and chemical and physical attributes of this invention willbe gained upon examination of the detailed description.

Also, it is understood that the phraseology and terminology used hereinare for the purpose of description and should not be regarded aslimiting. Throughout the specification and the claims which follow,unless the context requires otherwise, the use of “including,” “having,”and “comprising” and variations thereof herein is meant to encompass thestated integers and steps and equivalents thereof as well as additionalitems and equivalents thereof.

Throughout the specification, where compositions are described asincluding components or materials, it is contemplated that thecompositions can also consist essentially of, or consist of, anycombination of the recited components or materials, unless describedotherwise. Likewise, where methods are described as including particularsteps, it is contemplated that the methods can also consist essentiallyof, or consist of, any combination of the recited steps, unlessdescribed otherwise. The invention illustratively disclosed hereinsuitably may be practiced in the absence of any element or step which isnot specifically disclosed herein.

The foregoing description is given for clearness of understanding only,and no unnecessary limitations should be understood therefrom, asmodifications within the scope of the invention may be apparent to thosehaving ordinary skill in the art. All patents, publications andreferences cited herein are hereby fully incorporated by reference. Incase of conflict between the present disclosure and incorporatedpatents, publications and references, the present disclosure shouldcontrol.

What is claimed is:
 1. A pharmaceutical formulation for oraladministration comprising (a) a 25-hydroxyvitamin D compound (b) anagent that increases the risk of hypocalcemia, optionally cinacalcet ora salt thereof, and (c) an anticancer agent.
 2. The pharmaceuticalformulation of claim 1, comprising a first region comprising the25-hydroxyvitamin D compound and a second region comprising the agentthat increases the risk of hypocalcemia.
 3. The pharmaceuticalformulation of claim 2, wherein the first region comprising the25-hydroxyvitamin D compound further comprises a pharmaceuticallyacceptable excipient, or the second region that comprises the agent thatincreases the risk of hypocalcemia further comprises a pharmaceuticallyacceptable excipient, or both the first and second regions each furthercomprises a pharmaceutically acceptable excipient.
 4. The pharmaceuticalformulation of claim 1, comprising a matrix that releasably binds andcontrollably releases the 25-hydroxyvitamin D compound.
 5. Thepharmaceutical formulation of claim 1, comprising a wax matrixcomprising the 25-hydroxyvitamin D compound, a controlled release agent,an emulsifier, an absorption enhancer, and a stabilizing agent.
 6. Thepharmaceutical formulation of claim 1, comprising a matrix comprisingthe 25-hydroxyvitamin D compound, about 20 wt % paraffin, about 20 wt %to about 25 wt % glycerol monostearate, about 10 wt % a mixture oflauroyl macrogolglycerides and lauroyl polyoxylglycerides, about 30 wt %to about 35 wt % mineral oil, and about 10 wt % to about 15 wt %hydroxyl propyl methylcellulose.
 7. The pharmaceutical formulation ofclaim 1, wherein formulation or region comprising the 25-hydroxyvitaminD compound comprises a coating comprising a mixture of neutral swellablemethacrylic acids esters with trimethylammonioethyl methacrylatechlorides.
 8. The pharmaceutical formulation of claim 1, whereinformulation or region comprising the 25-hydroxyvitamin D compoundcomprises a coating comprising a one or more polyvinyl esters, polyvinylacetals, polyacrylic acid esters, butadiene sytrene copolymers, ormixtures thereof.
 9. The pharmaceutical formulation of claim 1,characterized by an in vitro dissolution profile providing release ofthe 25-hydroxyvitamin D compound of about 20% to about 40% at 2 hours,at least 35% at 6 hours, and at least 70% at 12 hours.
 10. Thepharmaceutical formulation of claim 1, characterized by an in vitrodissolution profile providing release of the agent that increases therisk of hypocalcemia of at least 50% at 30 minutes.
 11. Thepharmaceutical formulation of claim 1, wherein the formulation comprisesa capsule having a hard shell.
 12. The pharmaceutical formulation ofclaim 1, wherein the formulation comprises a soft capsule.
 13. Thepharmaceutical formulation of claim 1, comprising the agent thatincreases the risk of hypocalcemia disposed in a first capsule shell andthe 25-hydroxyvitamin D compound disposed in second capsule shell, thesecond capsule shell being disposed within the first capsule shell. 14.The pharmaceutical formulation of claim 1, comprising the agent thatincreases the risk of hypocalcemia in granular form.
 15. Thepharmaceutical formulation of claim 1, comprising a core regioncomprising the 25-hydroxyvitamin D compound and an outer regioncomprising the agent that increases the risk of hypocalcemia.
 16. Thepharmaceutical formulation of claim 1, wherein the agent that increasesthe risk of hypocalcemia is disposed within a coating.
 17. Thepharmaceutical formulation of claim 16, wherein the coating is disposedon at least one nonpareil.
 18. The pharmaceutical formulation of claim17, wherein one or more coated nonpareils are blended with the25-hydroxyvitamin D compound in a non-aqueous solution, the blend beingdisposed in a capsule shell.
 19. The pharmaceutical formulation of claim17, wherein the 25-hydroxyvitamin D compound is disposed in a firstchamber of a two-chamber capsule, and one or more coated nonpareils aredisposed in a second chamber of the two-chamber capsule.
 20. Thepharmaceutical formulation of claim 1, wherein the agent that increasesthe risk of hypocalcemia is formulated for rapid release.
 21. Thepharmaceutical formulation of claim 1, wherein the 25-hydroxyvitamin Dcompound is 25-hydroxyvitamin D₂, 25-hydroxyvitamin D₃, or a combinationthereof.
 22. The pharmaceutical formulation of claim 21, wherein the25-hydroxyvitamin D compound is 25-hydroxyvitamin D₃.
 23. Thepharmaceutical formulation of claim 1, comprising the 25-hydroxyvitaminD compound in an amount between about 1 mcg and about 1000 mcg.
 24. Thepharmaceutical formulation of claim 1, comprising the 25-hydroxyvitaminD compound in an amount between about 1 mcg and about 100 mcg.
 25. Thepharmaceutical formulation of claim 1, comprising the agent thatincreases the risk of hypocalcemia in an amount between about 1 mg andabout 100 mg.
 26. The pharmaceutical formulation of claim 1, wherein theagent that increases the risk of hypocalcemia comprises cinacalcet or asalt thereof.
 27. The pharmaceutical formulation of claim 26, whereinthe cinacalcet or salt thereof comprises cinacalcet HCl.
 28. Thepharmaceutical formulation of claim 1, further comprising adisintegrant, optionally in an amount of about 1 wt % to 10 wt %. 29.The pharmaceutical formulation of claim 2, wherein the region comprisingthe agent that increases the risk of hypocalcemia comprises from about10% to about 40% by weight of cinacalcet or a salt thereof, from about45% to about 85% by weight of at least one diluent, and from about 1% toabout 10% by weight of at least one disintegrant, optionally furthercomprising from about 1% to about 5% by weight of at least one binder,wherein the percentage by weight is relative to the total weight of theregion.
 30. The pharmaceutical formulation of claim 2, wherein theregion comprising the agent that increases the risk of hypocalcemiacomprises: (a) from about 10% to about 40% by weight of cinacalcet orsalt thereof; (b) from about 40% to about 75% by weight ofmicrocrystalline cellulose; (c) from about 5% to about 35% by weight ofstarch; (d) from about 1% to about 10% by weight of crospovidone; (e)from about 0.05% to about 1.5% by weight of colloidal silicon dioxide;and (f) from about 0.05% to about 1.5% by weight of magnesium stearate;wherein the percentage by weight is relative to the total weight of theregion.
 31. The pharmaceutical formulation of claim 2, wherein theregion comprising the agent that increases the risk of hypocalcemiacomprises: (a) from about 10% to about 40% by weight of cinacalcet orsalt thereof; (b) from about 40% to about 75% by weight ofmicrocrystalline cellulose; (c) from about 1% to about 5% by weight ofpovidone; (d) from about 5% to about 35% by weight of starch; (e) fromabout 0.05% to about 1.5% by weight of colloidal silicon dioxide; and(f) from about 0.05% to about 1.5% by weight of magnesium stearate;wherein the percentage by weight is relative to the total weight of theregion.
 32. The pharmaceutical formulation of claim 2, wherein theregion comprising the agent that increases the risk of hypocalcemiacomprises: (a) from about 10% to about 40% by weight of cinacalcet orsalt thereof; (b) from about 40% to about 75% by weight ofmicrocrystalline cellulose; (c) from about 15% to about 50% by weight ofstarch; (d) from about 0.05% to about 1.5% by weight of colloidalsilicon dioxide; and (e) from about 0.05% to about 1.5% by weight ofmagnesium stearate; wherein the percentage by weight is relative to thetotal weight of the region.
 33. The pharmaceutical formulation of claim2, wherein the region comprising the agent that increases the risk ofhypocalcemia comprises: (a) from about 10% to about 40% by weight ofcinacalcet or salt thereof; (b) from about 40% to about 75% by weight ofmicrocrystalline cellulose; (c) from about 1% to about 5% by weight ofpovidone; (d) from about 1% to about 10% by weight of a disintegrantselected from the group consisting of croscarmellose, sodium starchglycolate, crosslinked cellulose, crosslinked polymers, crosslinkedstarches, and combinations thereof; (e) from about 0.05% to about 1.5%by weight of colloidal silicon dioxide; and (f) from about 0.05% toabout 1.5% by weight of magnesium stearate; wherein the percentage byweight is relative to the total weight of the region.
 34. Thepharmaceutical formulation of claim 2, wherein the region comprising theagent that increases the risk of hypocalcemia comprises: (a) from about10% to about 40% by weight of cinacalcet or salt thereof; (b) from about40% to about 75% by weight of microcrystalline cellulose; (c) from about1% to about 5% by weight of a binder selected from the group consistingof gelatin, acacia, tragacanth, alginic acid, cellulose, methylcellulose, ethyl cellulose, HPMC, HPC, sodium carboxy methyl cellulose,PEG, PVA, polymethacrylate, polyvinylcaprolactam, and combinationsthereof; (d) from about 5% to about 35% by weight of starch; (e) fromabout 1% to about 10% by weight of crospovidone; (f) from about 0.05% toabout 1.5% by weight of colloidal silicon dioxide; and (g) from about0.05% to about 1.5% by weight of magnesium stearate; wherein thepercentage by weight is relative to the total weight of the region. 35.A method of managing iatrogenic hypocalcemia and secondaryhyperparathyroidism in a patient receiving therapy with cinacalcet or asalt thereof, comprising administering to said patient a pharmaceuticalformulation of claim
 1. 36. The method of claim 35, wherein the patienthas impaired renal function, optionally associated with Chronic KidneyDisease Stage 1, 2, 3, 4, or
 5. 37. The method of claim 35, wherein thepatient is receiving dialysis.
 38. The method of claim 35, wherein thepatient is not on dialysis.
 39. The method of claim 35, wherein theamount of 25-hydroxyvitamin D is effective to restore or maintain thepatient's serum calcium level to at least about 8.0 mg/dL, optionally ina range of about 8.3 mg/dL to about 11.6 mg/dL.
 40. The method of claim35, wherein the amount of 25-hydroxyvitamin D is effective to safelyincrease the patient's serum level of 25-hydroxyvitamin D to at least 30ng/mL, optionally in a range of about 30 ng/mL to about 100 ng/mL. 41.The method of claim 35, wherein the amount of 25-hydroxyvitamin D iseffective to decrease the patient's serum parathyroid hormone level,optionally by 30% or more.
 42. The method of claim 35, wherein theamount of 25-hydroxyvitamin D is administered in an oral modifiedrelease formulation, optionally a sustained release formulation.
 43. Themethod of claim 35, wherein the 25-hydroxyvitamin D is co-administeredwith an oral formulation comprising cinacalcet or a salt thereof. 44.The method of claim 35, wherein the 25-hydroxyvitamin D comprises25-hydroxyvitamin D₃, 25-hydroxyvitamin D₂, or a combination thereof.45. The method of claim 44, wherein the 25-hydroxyvitamin D comprises25-hydroxyvitamin D₃.
 46. The method of claim 35, wherein the25-hydroxyvitamin D is administered in a dosage of 1 mcg to 1000 mcg perday.
 47. The method of claim 35, wherein the cinacalcet or salt thereofcomprises cinacalcet HCl.
 48. The method of claim 35, wherein thepatient is receiving cinacalcet administered in a dosage of 1 mg to 400mg per day.
 49. A method of treating hypercalcemia in a patient withparathyroid carcinoma, comprising administering to said patient aneffective amount of a 25-hydroxyvitamin D compound by modified releaseand an effective dose of cinacalcet or a salt thereof in an amount ofless than 360 mg daily, wherein said effective amount of cinacalcet or asalt thereof is a reduced dose compared to the effective dose ofcinacalcet in the absence of said 25-hydroxyvitamin D administration,and an anticancer agent.
 51. The method of claim 49, comprising aninitial dose of cinacalcet in a rage of about 20 mg to about 25 mg oncedaily.
 52. The method of claim 49, wherein the amount of25-hydroxyvitamin D is in a range of about 100 mcg to about 300 mcg. 53.The pharmaceutical formulation of claim 1, wherein the anticancer agentcomprises one or more agents in the groups including aromataseinhibitors; anti-estrogens; anti-androgens; gonadorelin agonists;topoisomerase I inhibitors; topoisomerase II inhibitors; microtubuleactive agents; alkylating agents; retinoids, carotenoids, tocopherols;cyclooxygenase inhibitors; MMP inhibitors; mTOR inhibitors;antimetabolites; platin compounds; methionine aminopeptidase inhibitors;bisphosphonates; antiproliferative antibodies; heparanase inhibitors;inhibitors of Ras oncogenic isoforms; telomerase inhibitors; proteasomeinhibitors; Flt-3 inhibitors; Hsp90 inhibitors; kinesin spindle proteininhibitors; MEK inhibitors; antitumor antibiotics; nitrosoureas,compounds targeting/decreasing protein or lipid kinase activity,compounds targeting/decreasing protein or lipid phosphatase activity,antiangiogenic compounds, azacitidine, axathioprine, bevacizumab,bleomycin, capecitabine, carboplatin, chlorabucil, cisplatin,cyclophosphamide, cytarabine, daunorubicin, docetaxel, doxifluridine,doxorubicin, epirubicin, etoposide, fluorouracil, gemcitabine,herceptin, idarubicin, mechlorethamine, melphalan, mercaptopurine,methotrexate, mitoxantrone, oxaliplatin, paclitaxel, tafluposide,teniposide, tioguanine, retinoic acid, valrubicin, vinblastine,vincristine, vindesine, vinorelbine, and receptor tyrosine kinaseinhibitors.
 54. The pharmaceutical formulation of claim 53, wherein theanticancer agent comprises one or more aromatase inhibitors.
 55. Thepharmaceutical formulation of claim 53, wherein the anticancer agentcomprises one or more anti-estrogens.
 56. The pharmaceutical formulationof claim 53, wherein the anticancer agent comprises one or moreanti-androgens.
 57. The pharmaceutical formulation of claim 53, whereinthe anticancer agent comprises one or more gonadorelin agonists.
 58. Thepharmaceutical formulation of claim 53, wherein the anticancer agentcomprises one or moretopoisomerase I inhibitors.
 59. The pharmaceuticalformulation of claim 53, wherein the anticancer agent comprises one ormore topoisomerase II inhibitors.
 60. The pharmaceutical formulation ofclaim 53, wherein the anticancer agent comprises one or more microtubuleactive agents.
 61. The pharmaceutical formulation of claim 53, whereinthe anticancer agent comprises one or more alkylating agents.
 62. Thepharmaceutical formulation of claim 53, wherein the anticancer agentcomprises one or more retinoids.
 63. The pharmaceutical formulation ofclaim 53, wherein the anticancer agent comprises one or morecarotenoids.
 64. The pharmaceutical formulation of claim 53, wherein theanticancer agent comprises one or more tocopherols.
 65. Thepharmaceutical formulation of claim 53, wherein the anticancer agentcomprises one or more cyclooxygenase inhibitors.
 66. The pharmaceuticalformulation of claim 53, wherein the anticancer agent comprises one ormore MMP inhibitors.
 67. The pharmaceutical formulation of claim 53,wherein the anticancer agent comprises one or more mTOR inhibitors. 68.The pharmaceutical formulation of claim 53, wherein the anticancer agentcomprises one or more antimetabolites.
 69. The pharmaceuticalformulation of claim 53, wherein the anticancer agent comprises one ormore platin compounds.
 70. The pharmaceutical formulation of claim 53,wherein the anticancer agent comprises one or more methionineaminopeptidase inhibitors.
 71. The pharmaceutical formulation of claim53, wherein the anticancer agent comprises one or more bisphosphonates.72. The pharmaceutical formulation of claim 53, wherein the anticanceragent comprises one or more antiproliferative antibodies.
 73. Thepharmaceutical formulation of claim 53, wherein the anticancer agentcomprises one or more heparanase inhibitors.
 74. The pharmaceuticalformulation of claim 53, wherein the anticancer agent comprises one ormore inhibitors of Ras oncogenic isoforms.
 75. The pharmaceuticalformulation of claim 53, wherein the anticancer agent comprises one ormore telomerase inhibitors.
 76. The pharmaceutical formulation of claim53, wherein the anticancer agent comprises one or more proteasomeinhibitors.
 77. The pharmaceutical formulation of claim 53, wherein theanticancer agent comprises one or more Flt-3 inhibitors.
 78. Thepharmaceutical formulation of claim 53, wherein the anticancer agentcomprises one or more Hsp90 inhibitors.
 79. The pharmaceuticalformulation of claim 53, wherein the anticancer agent comprises one ormore kinesin spindle protein inhibitors.
 80. The pharmaceuticalformulation of claim 53, wherein the anticancer agent comprises one ormore MEK inhibitors.
 81. The pharmaceutical formulation of claim 53,wherein the anticancer agent comprises one or more antitumorantibiotics.
 82. The pharmaceutical formulation of claim 53, wherein theanticancer agent comprises one or more nitrosoureas.
 83. Thepharmaceutical formulation of claim 53, wherein the anticancer agentcomprises one or more compounds targeting/decreasing protein or lipidkinase activity.
 84. The pharmaceutical formulation of claim 53, whereinthe anticancer agent comprises one or more compoundstargeting/decreasing protein or lipid phosphatase activity.
 85. Thepharmaceutical formulation of claim 53, wherein the anticancer agentcomprises one or more antiangiogenic compounds.
 86. The pharmaceuticalformulation of claim 53, wherein the anticancer agent comprisesazacitidine.
 87. The pharmaceutical formulation of claim 53, wherein theanticancer agent comprises axathioprine.
 88. The pharmaceuticalformulation of claim 53, wherein the anticancer agent comprisesbevacizumab.
 89. The pharmaceutical formulation of claim 53, wherein theanticancer agent comprises bleomycin.
 90. The pharmaceutical formulationof claim 53, wherein the anticancer agent comprises capecitabine. 91.The pharmaceutical formulation of claim 53, wherein the anticancer agentcomprises carboplatin.
 92. The pharmaceutical formulation of claim 53,wherein the anticancer agent comprises chlorabucil.
 93. Thepharmaceutical formulation of claim 53, wherein the anticancer agentcomprises cisplatin.
 94. The pharmaceutical formulation of claim 53,wherein the anticancer agent comprises cyclophosphamide.
 95. Thepharmaceutical formulation of claim 53, wherein the anticancer agentcomprises cytarabine.
 96. The pharmaceutical formulation of claim 53,wherein the anticancer agent comprises daunorubicin.
 97. Thepharmaceutical formulation of claim 53, wherein the anticancer agentcomprises docetaxel.
 98. The pharmaceutical formulation of claim 53,wherein the anticancer agent comprises doxifluridine.
 99. Thepharmaceutical formulation of claim 53, wherein the anticancer agentcomprises doxorubicin.
 100. The pharmaceutical formulation of claim 53,wherein the anticancer agent comprises epirubicin.
 101. Thepharmaceutical formulation of claim 53, wherein the anticancer agentcomprises etoposide.
 102. The pharmaceutical formulation of claim 53,wherein the anticancer agent comprises fluorouracil.
 103. Thepharmaceutical formulation of claim 53, wherein the anticancer agentcomprises gemcitabine.
 104. The pharmaceutical formulation of claim 53,wherein the anticancer agent comprises herceptin.
 105. Thepharmaceutical formulation of claim 53, wherein the anticancer agentcomprises idarubicin.
 106. The pharmaceutical formulation of claim 53,wherein the anticancer agent comprises mechlorethamine.
 107. Thepharmaceutical formulation of claim 53, wherein the anticancer agentcomprises melphalan.
 108. The pharmaceutical formulation of claim 53,wherein the anticancer agent comprises mercaptopurine.
 109. Thepharmaceutical formulation of claim 53, wherein the anticancer agentcomprises methotrexate.
 110. The pharmaceutical formulation of claim 53,wherein the anticancer agent comprises mitoxantrone.
 111. Thepharmaceutical formulation of claim 53, wherein the anticancer agentcomprises oxaliplatin.
 112. The pharmaceutical formulation of claim 53,wherein the anticancer agent comprises paclitaxel.
 113. Thepharmaceutical formulation of claim 53, wherein the anticancer agentcomprises tafluposide.
 114. The pharmaceutical formulation of claim 53,wherein the anticancer agent comprises teniposide.
 115. Thepharmaceutical formulation of claim 53, wherein the anticancer agentcomprises tioguanine.
 116. The pharmaceutical formulation of claim 53,wherein the anticancer agent comprises retinoic acid.
 117. Thepharmaceutical formulation of claim 53, wherein the anticancer agentcomprises valrubicin.
 118. The pharmaceutical formulation of claim 53,wherein the anticancer agent comprises vinblastine.
 119. Thepharmaceutical formulation of claim 53, wherein the anticancer agentcomprises vincristine.
 120. The pharmaceutical formulation of claim 53,wherein the anticancer agent comprises vindesine.
 121. Thepharmaceutical formulation of claim 53, wherein the anticancer agentcomprises vinorelbine.
 122. The pharmaceutical formulation of claim 53,wherein the anticancer agent comprises one or more receptor tyrosinekinase inhibitors.